

1 **Pericyte-mediated constriction of renal capillaries evokes no-reflow and kidney injury following**
2 **ischaemia**

3 Felipe Freitas and David Attwell

4
5 Department of Neuroscience, Physiology & Pharmacology

6 Andrew Huxley Building

7 University College London

8 Gower Street, London, WC1E 6BT, UK

9
10 **Running title: Pericytes mediate post-ischaemic renal no-reflow**

11
12 **Address correspondence to:**

13 David Attwell

14 Email: d.attwell@ucl.ac.uk

15 Tel (+44)-20-7679-7342

16 Department of Neuroscience, Physiology & Pharmacology

17 Andrew Huxley Building

18 University College London

19 Gower Street, London, WC1E 6BT, UK

20 **Keywords:** Renal ischaemia; no-reflow; pericytes; kidney injury; descending vasa recta; peritubular
21 capillaries.

22 **Abstract**

23 Acute kidney injury is common, with ~13 million cases and 1.7 million deaths/year worldwide. A major
24 cause is renal ischaemia, typically following cardiac surgery, renal transplant or severe hemorrhage.
25 We examined the cause of the sustained reduction in renal blood flow (“no-reflow”), which exacerbates
26 kidney injury even after an initial cause of compromised blood supply is removed. Adult male Sprague-
27 Dawley rats, or NG2-dsRed male mice were used in this study. After 60 min kidney ischaemia and 30-
28 60 min reperfusion, renal blood flow remained reduced, especially in the medulla, and kidney tubule
29 damage was detected as Kim-1 expression. Constriction of the medullary descending vasa recta and
30 cortical peritubular capillaries occurred near pericyte somata, and led to capillary blockages, yet
31 glomerular arterioles and perfusion were unaffected, implying that the long-lasting decrease of renal
32 blood flow contributing to kidney damage was generated by pericytes. Blocking Rho kinase to decrease
33 pericyte contractility from the start of reperfusion increased the post-ischaemic diameter of the
34 descending vasa recta capillaries at pericytes, reduced the percentage of capillaries that remained
35 blocked, increased medullary blood flow and reduced kidney injury. Thus, post-ischaemic renal no-
36 reflow, contributing to acute kidney injury, reflects pericytes constricting the descending vasa recta and
37 peritubular capillaries. Pericytes are therefore an important therapeutic target for treating acute kidney
38 injury.

39 **Introduction**

40 The global burden of acute kidney injury is approximately 13 million cases a year (Ponce &
41 Balbi, 2016). It is associated with a high mortality (1.7 million deaths per year, worldwide) (Gameiro
42 et al., 2018; Hoste et al., 2018; Mehta et al., 2016), and COVID-19 has added to its incidence (Ronco
43 et al., 2020). Renal ischaemia followed by reperfusion, which can occur after cardiac surgery, renal
44 transplant or severe hemorrhage, is the most common cause of acute kidney injury (Lameire et al., 2006;
45 Lameire & Vanholder, 2001). Sustained renal blood flow reductions occur after ischaemia and
46 reperfusion, both in experimental studies and in patients after kidney transplantation (Cristol et al.,
47 1996; Nijveldt et al., 2001; Ramaswamy et al., 2002). Following short periods of ischaemia, blood flow
48 to the renal cortex largely recovers following reperfusion, but medullary blood flow remains reduced
49 for a prolonged period, especially in the hypoxia-sensitive outer medulla (the organisation of kidney
50 areas and vasculature is shown in our summary Figure 8 below). Medullary no-reflow is a critical event
51 for amplifying renal tissue injury following reperfusion (Conesa et al., 2001; Olof et al., 1991; Regner
52 et al., 2009).

53 Renal no-reflow has been attributed to various causes, including impaired erythrocyte
54 movement and leukocyte accumulation in renal capillaries, as well as increased intratubular pressure
55 (Bonventre & Weinberg, 2003; Sutton et al., 2002; Wei et al., 2017; Yamamoto et al., 2002). However,
56 after years of investigation, no effective treatment is available, even though no-reflow predicts a worse
57 prognosis after kidney ischaemia. We therefore investigated an alternative possible cause of no-reflow,
58 i.e. ischaemia-evoked contraction of pericytes that regulate capillary diameter, which might reduce
59 renal blood flow and physically trap red blood cells. Indeed, in the brain and heart contractile pericytes
60 on capillaries play a key role in reducing blood flow after ischaemia (Hall et al., 2014; O'Farrell et al.,
61 2017; Yemisci et al., 2009) because capillaries remain constricted by pericytes even when blood flow
62 is restored to upstream arterioles. In the retina it has been shown that this capillary constriction is
63 mediated by α -smooth muscle actin (α -SMA) based actomyosin-mediated contraction of capillary
64 pericytes (Alarcon-Martinez et al., 2019). In the kidney, pericytes are associated with the cortical and
65 medullary peritubular capillaries and the descending vasa recta. As in the retina, pericyte populations

66 in the kidney, particularly those in the descending vasa recta, are associated with α -SMA expression
67 and contractility (Park et al., 1997; Shaw et al., 2018). They play a key role in regulating renal medullary
68 blood flow (Crawford et al., 2012; Pallone & Sillardorff, 2001) which is a crucial variable for meeting
69 the contradictory demands of preserving cortico-medullary osmotic gradients to allow water retention
70 in the body, while maintaining adequate oxygen and nutrient delivery. This raises the question of
71 whether pericytes also play a role in generating renal no-reflow after ischaemia.

72 An important regulator of pericyte contractility is the Rho kinase pathway (Durham et al., 2014;
73 Kutcher et al., 2007), which inhibits myosin phosphatase, thus increasing phosphorylation of myosin
74 light chain (MLC) and increasing contraction (Kimura et al., 1996; Maeda et al., 2003). Overactivity of
75 Rho kinase may play a key role in hypertension and diabetes, as well as in kidney ischaemia (Jahani et
76 al., 2018; Kushiyama et al., 2013; Peng et al., 2008; Soga et al., 2011; Versteilen et al., 2006). Rho
77 kinase may also regulate pericyte contractility by modulating actin polymerization (Kureli et al., 2020;
78 Kutcher & Herman, 2009; Maekawa et al., 1999; Zhang et al., (2018a). In ischaemia, an important
79 pathway by which Rho kinase inhibits myosin phosphatase is via inactivation of endothelial nitric oxide
80 synthase (eNOS) (Versteilen et al., 2006), thus reducing production of nitric oxide (NO). NO acts on
81 guanylate cyclase to raise the concentration of cyclic GMP, which increases MLC phosphatase activity
82 and thus decreases contraction, so inhibiting eNOS will increase MLC phosphorylation and contraction.
83 Thus, both the direct effect of Rho kinase (Kimura et al., 1996; Maeda et al., 2003) and its actions on
84 eNOS (Versteilen et al., 2006) converge to promote MLC phosphorylation and contraction. Rho kinase
85 is an important effector of vasoconstrictors such as endothelin-1 (Prakash et al., 2008; Wilhelm et al.,
86 1999; Yamamoto et al., 2000) and angiotensin II (Rupérez et al., 2005), but its effects on pericytes are
87 under-studied, although it may control their contractility (Durham et al., 2014; Hartmann et al., 2021;
88 Homma et al., 2014; Kutcher et al., 2007; Pearson et al., 2013).

89 Few studies have investigated how ischaemia affects renal pericytes (Kwon et al., 2008;
90 McCurley et al., 2017; Zhang et al., (2018b), and whether pericytes contribute to renal no-reflow.
91 However, peritubular pericytes are damaged in cortical tissue of cadaveric renal allografts following
92 ischaemia-reperfusion (Kwon et al., 2008), suggesting that renal blood flow control may be disrupted

93 after ischaemia by pericyte dysfunction. Here we show that pericyte-mediated capillary constriction,
94 especially of the descending vasa recta, makes a crucial contribution to no-reflow following renal
95 ischaemia and reperfusion. We further show that targeting pericyte-mediated constriction
96 pharmacologically can reduce ischaemia-evoked acute kidney injury.

97 **Results**

98 **No-reflow after renal ischaemia and reperfusion**

99 Adult male Sprague-Dawley rats (P40-50), or NG2-dsRed male mice (P100-120) were used in
100 this study. We used a combination of laser Doppler perfusion measurements, low magnification
101 imaging of blood volume, and high magnification imaging that resolved individual capillaries, to assess
102 the magnitude and cause of changes of renal perfusion after ischaemia. Ischaemia for 1 hour decreased
103 perfusion of the renal medulla and cortex by ~90% (both $p < 0.0001$ vs. control; assessed with laser
104 Doppler: Figure 1a, b). After 30 min reperfusion, blood flow recovered to 49% of control (significantly
105 reduced, $P = 0.005$, Figure 1a) in the medulla, but to 75% in the cortex ($P = 0.047$, Figure 1b) (Regner
106 et al., 2009). Perfusion was stable in the contralateral kidney throughout (Figure 1a, b). After 60 min
107 reperfusion, medullary perfusion remained compromised at 40% of the control level ($P = 0.017$, Figure
108 1-figure supplement 1a), but cortical perfusion had fully recovered (to ~20% above the control value,
109 not significant, $P = 0.092$, Figure 1-figure supplement 1b). Despite this flow recovery, we show below
110 that peritubular capillaries in the cortex can become blocked after ischaemia.

111 After ischaemia and reperfusion *in vivo*, assessing the volume of perfused vessels in fixed
112 kidney slices, as the summed FITC-albumin intensity over ROIs, also demonstrated that renal ischaemia
113 and reperfusion led to no-reflow in the medulla compared with the non-ischaemic kidney's medulla (the
114 perfusing blood volume was reduced by ~50%, $P = 0.002$; Figure 1c, d, f). Microscopic analysis
115 resolving individual capillaries showed that this blood volume reduction was associated with a large
116 reduction in capillary perfusion (Figure 2). The total perfused capillary length in 100 μm deep confocal
117 z-stacks (frame size 640.17x 640.17 μm) was reduced by 35% (contralateral control $14689 \pm 3477 \mu\text{m}$
118 vs. ischaemia $9527 \pm 1183 \mu\text{m}$, $P = 0.038$), the number of perfused capillary segments was reduced by

119 54% (control 530 ± 82 vs. ischaemia 244 ± 30 , $P=0.03$), and the overall perfused microvascular volume
120 fraction was reduced by 51% (control 0.116 ± 0.006 vs. ischaemia 0.057 ± 0.006 , $P=0.003$; Figure 2e-g).

121 In the cortex, perfusion was reduced less than in the medulla after ischaemia and reperfusion,
122 i.e. by 23.5% compared with non-ischaemic kidneys ($P=0.0075$, Figure 1c, d, g). Furthermore, although
123 a small percentage of afferent and efferent arterioles, and glomeruli, were not perfused in control
124 conditions, this percentage did not increase significantly after ischaemia (Figure 3a, b, g), and the
125 arterioles' diameter was not reduced compared with those in non-ischaemic kidneys (Figure 3a, b, h, i).
126 Similarly, it has been reported that upstream arteries are not constricted after ischaemia (Yamamoto et
127 al., 2002). In contrast, the total perfused peritubular capillary length in the 100 μm deep z-stacks (control
128 16441 ± 1577 μm vs. ischaemia 5411 ± 2735 μm , reduced by 67%, $P=0.03$), the number of perfused
129 capillary segments (control 550 ± 32 μm vs. ischaemia 349 ± 54 , reduced by 36.5%, $P=0.01$) and the
130 overall perfused peritubular capillary volume fraction (control 0.12 ± 0.01 vs. ischaemia 0.06 ± 0.02 ,
131 reduced by 50%, $P=0.01$) were greatly reduced in the cortex when compared with non-ischaemic
132 kidneys (Figure 3d-f). Thus, the effect of ischaemia and reperfusion is predominantly on the
133 microvasculature, i.e. the peritubular cortical capillaries and the vasa recta, rather than on arteriolar
134 segments of the kidney circulation. The Rho kinase inhibition data shown in Fig. 3 are discussed below.

135 **Pericytes constrict descending vasa recta after ischaemia and reperfusion**

136 Higher magnification images demonstrated that, in control kidneys, only 9.7% of the
137 descending vasa recta (DVR) capillaries were blocked (Figures 2b, 4d), i.e. were not perfused by FITC-
138 albumin (Figures 2c, 4a-d). However, after ischaemia and 30 mins reperfusion, 78% of the DVR
139 capillaries were blocked (Figures 2c, 4a-d). Some capillaries were fully perfused and some completely
140 unperfused throughout the area assessed, whereas some exhibited an abrupt cessation of blood flow
141 with a decrease of FITC-albumin intensity over a few microns (Figures 2c, 4a-c). At block sites, the
142 diameter of the FITC-albumin luminal labeling at the final position blood reached was significantly
143 lower in ischaemic DVR capillaries compared with that at the much smaller number of block sites in
144 non-ischaemic controls (control 6.5 ± 0.3 μm vs. ischaemia 3.5 ± 0.4 μm ; $P=0.039$, Figure 4e). Thus, an
145 ischaemia-induced constriction of the DVR promotes blockage, which persists even after reperfusion.

146 Erythrocyte protein glycoprotein A was labelled to assess if red blood cells were trapped at
147 capillary regions of reduced diameter. Red blood cells were associated with only a small percentage of
148 blockage sites in ischaemic kidneys (5.8% of 85 blockages in 137 vessels from 2 animals), and even
149 where red blood cells were near the capillary blockages they did not always block blood flow because
150 FITC-albumin could pass the red blood cells (Figure 4-figure supplement 1a, b).

151 In the brain (Hall et al., 2014; Yemisci et al., 2009) and heart (O'Farrell et al., 2017) post-
152 ischaemic capillary constriction reflects pericyte contraction, which occurs near pericyte somata where
153 circumferential processes originate (Nortley et al., 2019). From NG2 labelling we observed that many
154 DVR blockages were close to pericyte somata, or near to pericyte circumferential processes connected
155 to the soma (Figure 4b-c), suggesting that contraction of these juxta-somatic processes evoked capillary
156 block. We measured the distance of 27 blockages to the nearest pericyte soma. The probability
157 distribution of this distance is compared with that of the inter-pericyte distance in Figure 4f (if blocks
158 did not depend on pericytes, the probability distribution of the blockage-pericyte distance would be
159 constant until half the distance between pericytes). The mean blockage-pericyte distance was 4.87 ± 0.33
160 μm after ischaemia and reperfusion, which is less than a quarter of the distance between DVR pericytes
161 ($22.85 \pm 0.93 \mu\text{m}$, from 118 pericyte pairs). Thus, these data are consistent with pericyte constriction
162 generating the DVR blockages.

163 In control conditions, the few blockages occurring were mainly in regions where the inter-
164 pericyte distance was larger. The mean distance from a blockage to the nearest pericyte soma was also
165 larger ($14.98 \pm 1.36 \mu\text{m}$, $p < 0.0001$ compared to post-ischaemia), suggesting a different block mechanism
166 in control conditions.

167 To assess pericyte-mediated DVR constriction further, we measured the FITC-albumin labelled
168 lumen diameter at 5 micron intervals upstream of pericyte somata (upstream so there was FITC-albumin
169 in the vessel: Figure 4g). After ischaemia and reperfusion, the diameter was significantly reduced (by
170 41%, $p = 0.0001$) near the pericyte somata compared with non-ischaemic kidneys, but less reduced
171 further from the somata. The diameter significantly increased with distance from the somata after
172 ischaemia and reperfusion ($P = 0.039$ comparing the slope of the best-fit ischaemia regression line with

173 zero) but not in control conditions ($P=0.084$), implying constriction preferentially near the pericyte
174 somata (Figure 4g) and identifying pericytes as the origin of the diameter reduction. Such constrictions
175 will reduce blood flow directly by increasing the vascular resistance, and may also lead to blood cells
176 becoming trapped at the regions of narrowed diameter, thus occluding the vessel and further reducing
177 blood flow.

178 We assessed whether the endothelial glycocalyx (eGCX) contributed to DVR blockages.
179 Labelling showed that eGCX is fairly uniformly present along capillaries, and this was not altered after
180 ischaemia (Figure 4-figure supplement 1f-g). There was no correlation between eGCX intensity and
181 capillary diameter in control or ischaemic conditions (Figure 4-figure supplement 1h). Thus, eGCX is
182 not particularly associated with pericytes (Figure 4-figure supplement 1f), so the co-location of diameter
183 reduction and blockages with pericyte somata presumably reflects pericyte process contraction rather
184 than obstruction by eGCX.

185 **Pericytes constrict peritubular cortical capillaries *in vivo* after ischaemia and reperfusion**

186 Two-photon microscopy *in vivo*, of mice expressing dsRed in pericytes, revealed peritubular
187 cortical pericytes constricting and blocking capillaries after ischaemia and reperfusion (Figure 5a-c).
188 This reduced the mean capillary diameter (averaged over all positions measured) from 10.8 ± 0.2 to
189 8.1 ± 0.5 μm ($p<0.0001$). To quantify whether ischaemia-evoked blockages occurred disproportionately
190 close to pericytes, we measured the distance of 15 blockages to the nearest pericyte soma. This distance
191 was 4.12 ± 0.39 μm , which is only 10% of the mean distance between peritubular cortical pericytes
192 (41.3 ± 2.6 μm , from 103 pericyte pairs). A plot of capillary diameter versus distance from pericyte
193 somata (Figure 5d) showed that ischaemia and reperfusion reduced the diameter by 40% at the somata
194 (control 11.2 ± 0.5 vs. ischaemia 6.76 ± 1.05 μm , $P=0.001$) with no significant effect on diameter far from
195 the somata (control 10.3 ± 0.2 μm vs. ischaemia 9.6 ± 0.5 μm , $P=0.115$). As in the medulla, the diameter
196 increased significantly with distance from the pericyte somata after ischaemia ($P=0.046$ comparing the
197 slope of the best-fit regression line with zero) while in control conditions it did not (diameter decreased
198 insignificantly with distance, $P=0.10$). Thus, capillaries are constricted specifically near cortical
199 pericytes.

200 The fact that pericyte constriction of capillaries reduces blood flow more in the medulla than
201 in the cortex (Figure 1) may at least partly reflect differences in pericyte number and morphology in
202 these two regions. The mean distance between pericytes in the medulla (23 μm , see above) is roughly
203 half that in the cortex (41 μm , see above). Furthermore, in general the morphology of pericytes differs
204 in these two regions, with DVR pericytes showing many circumferential processes around the
205 capillaries, while cortical pericytes exhibit mainly longitudinal processes running along the capillary
206 with only a small number of circumferential processes (Figure 4-figure supplement 2). The small
207 number of vessel branches in the medullary DVR implies that the class of pericyte associated with
208 branch points that is found in the brain vasculature will be less common here.

209 **Rho kinase inhibition reduces pericyte constriction and no-reflow**

210 The contractility of pericytes depends partly on Rho kinase activity (Durham et al., 2014;
211 Hirunpattarasilp et al., 2019; Homma et al., 2014; Kutcher et al., 2007). The Rho kinase inhibitor,
212 hydroxyfasudil (3 mg/kg; i.v.), applied at the time of reperfusion to mimic a possible therapeutic
213 intervention, significantly inhibited the decrease of renal medullary perfusion seen after ischaemia-
214 reperfusion (Figure 1a, e-f). *In vivo*, blood flow in the medulla (after 30 mins reperfusion) was increased
215 3.8-fold compared to ischaemia without hydroxyfasudil ($P=0.002$, Figure 1a). Hydroxyfasudil induced
216 a faster recovery of medullary blood flow than BQ123 (0.5 mg/kg, i.v.), an endothelin A receptor
217 antagonist (Figure 1-figure supplement 1c), but both resulted in blood flow at 30 mins reperfusion that
218 was not significantly different from the control value ($P=0.8$ and 0.38 respectively) and was
219 significantly higher than the flow seen after ischaemia without either drug ($P=0.01$ for both drugs). In
220 contrast, the angiotensin II type 1 (AT1) receptor antagonist valsartan (1 mg/kg i.v.) speeded the initial
221 post-ischaemic recovery of medullary blood flow, but did not return it to baseline by 30 mins
222 reperfusion (Figure 1-figure supplement 1c). In the cortex, blood flow recovery on reperfusion was
223 speeded by hydroxyfasudil and, after 30 mins of reperfusion, was increased 1.48-fold compared to
224 ischaemia alone ($P= 0.02$, Figure 1b). These data suggest that, in the medulla especially, activation of
225 Rho kinase (in part downstream of ischaemia-evoked activation of endothelin A receptors (Prakash et

226 al., 2008; Wilhelm et al., 1999; Yamamoto et al., 2000)) contributes to ischaemia-evoked pericyte-
227 mediated capillary constriction.

228 Renal perfusion with post-ischaemic inhibition of Rho kinase was also assessed in slices of
229 fixed kidney (see above). Treatment with hydroxyfasudil during post-ischaemic reperfusion prevented
230 medullary no-reflow after ischaemia and reperfusion: the blood volume was increased 2.3-fold
231 compared to ischaemia alone ($P=0.003$, Figure 1e-f), so that it did not differ significantly from that in
232 control kidney ($P=0.47$). Hydroxyfasudil also increased ~2.9-fold the total perfused medullary capillary
233 length ($P = 0.043$), ~2.9-fold the number of perfused capillary segments ($P=0.02$) and ~2-fold the
234 perfused volume fraction ($P=0.0031$) in medulla (Figure 2d-g). In the renal cortex, hydroxyfasudil given
235 on reperfusion increased perfusion (blood volume) ~1.25-fold ($P=0.0098$; Figure 1e, g), and increased
236 the total perfused length of capillaries, the number of perfused capillary segments and the blood volume
237 fraction to values that were not significantly different from those in non-ischaemic kidneys (Figure 3c-
238 f).

239 **Improvements of renal blood flow by hydroxyfasudil are via pericytes, not arterioles**

240 Hydroxyfasudil might act on arteriolar smooth muscle or pericytes, or both. However, it had no
241 effect on the diameter of afferent or efferent arterioles feeding and leaving the glomeruli (Figure 3h, i).
242 In contrast, hydroxyfasudil reduced the constriction evoked at DVR pericyte somata by ischaemia and
243 reperfusion, increasing the diameter from $4.5\pm 0.5\ \mu\text{m}$ without hydroxyfasudil to $8.0\pm 0.4\ \mu\text{m}$ with the
244 drug ($p<0.0001$) (Figure 4g), and reduced the percentage of DVR capillaries blocked from $78\pm 9\%$ to
245 $8\pm 5\%$ ($P=0.023$), both of which are not significantly different from the values in non-ischaemic kidneys
246 (Figure 4d, f). Thus, ischaemia induces, and hydroxyfasudil decreases, medullary no-reflow by
247 specifically acting on DVR capillary pericytes rather than on upstream arterioles.

248 **Rho kinase inhibition reduces myosin light chain phosphorylation after ischaemia**

249 Rho kinase can inhibit, either directly or by inhibiting eNOS (Riddick et al., 2008; Wang et al.,
250 2009; Versteilen et al., 2006), myosin light chain phosphatase (MLCP), thus increasing phosphorylation
251 of myosin light chain (MLC) by myosin light chain kinase (MLCK) and increasing pericyte contraction,
252 but it also has other functions. To investigate how Rho kinase inhibition has the effects described above,

253 we labelled for phosphorylated MLC. After ischaemia and reperfusion, this was increased ~11-fold for
254 medullary and 5-fold for cortical pericytes ($P=0.0001$ in both locations, Figure 6a-j). Hydroxyfasudil
255 treatment after reperfusion reduced this increase so that the labelling was not significantly different
256 from that in control kidneys ($P=0.95$ and $P=0.56$ respectively; Figure 6a-j). Thus, if pericyte contraction
257 is via conventional smooth muscle actomyosin, the reduced MLC phosphorylation could explain the
258 pericyte relaxation and increased blood flow evoked by Rho kinase inhibition. The data of Versteilen
259 et al. (2006) suggest this is very largely mediated by inhibition of eNOS, which could be tested by
260 quantifying the effect of eNOS block on the changes of MLC phosphorylation shown in Figure 6.
261 Consistent with pericytes employing smooth muscle actomyosin, 56% of DVR pericytes near blockage
262 sites labeled for the contractile protein α -SMA (Figure 6k-n; see also (Park et al., 1997).

263 **Rho kinase inhibitor reduces reperfusion-induced acute kidney injury**

264 Kidney injury molecule-1 (Kim-1) is a sensitive and early diagnostic indicator of renal injury
265 in rodent kidney injury models (Vaidya et al., 2010), and in pathology is localized at high levels on the
266 apical membrane of the proximal tubule where the tubule is most affected (Amin et al., 2004; Ichimura
267 et al., 1998). Kim-1 levels in the proximal tubules were elevated 81-fold by ischaemia and reperfusion
268 ($P=0.0004$, Figure 7a, b, d), and treatment with hydroxyfasudil during reperfusion halved the Kim-1
269 labelling ($P=0.03$, Figure 7c, d).

270

271 **Discussion**

272 This paper demonstrates, for the first time, that the long-lasting decrease of renal blood flow
273 that follows transient ischaemia is generated by pericyte-mediated constriction and block of the
274 descending vasa recta and cortical peritubular capillaries, as schematised in the summary of Figure 8,
275 and that this post-ischaemic no-reflow can be reduced pharmacologically. We found *in vivo* that sites
276 of ischaemia-evoked medullary and cortical capillary block were associated with pericyte locations.
277 Furthermore, after ischaemia and reperfusion, the diameters of descending vasa recta and peritubular
278 capillaries were reduced specifically near pericyte somata, which extend contractile circumferential
279 processes around the capillaries. In contrast, cortical arteriole diameters were not reduced and glomeruli
280 remained perfused. The fact that capillary diameters are reduced specifically near pericyte somata

281 establishes that this is due to a contraction of the circumferential processes of pericytes, and not (for
282 example) due to a decrease in overall perfusion pressure (which would also reduce the diameter of
283 capillaries away from pericyte somata). Together, these data establish pericyte-mediated capillary
284 constriction as a major therapeutic target for treating post-ischaemic renal no-reflow.

285 Pericyte-mediated constriction of renal capillaries may reflect reduced Ca^{2+} pumping in
286 ischaemia, raising $[\text{Ca}^{2+}]_i$ which activates contraction, as for CNS pericytes (Hall et al., 2014).
287 Constriction may also partly reflect a release of angiotensin II (Allred et al., 2000; Boer et al., 1997; da
288 Silveira et al., 2010; Miyata et al., 1999; Sanchez-Pozos et al., 2012; Zhang et al., 2004) and endothelin
289 1 (Afyouni et al., 2015; Jones et al., 2020; Sanchez-Pozos et al., 2012) which raise $[\text{Ca}^{2+}]_i$ and Rho
290 kinase activity (Lee et al., 2014; Shimokawa & Rashid, 2007), since we found that blocking endothelin
291 A receptors and, to a lesser extent, angiotensin II receptors improved post-ischaemic renal blood flow.
292 Consistent with this, it has been demonstrated that vasoconstricting endothelin A (Crawford et al., 2012;
293 Wendel et al., 2006) and angiotensin II type 1 (AT1) (Crawford et al., 2012; Miyata et al., 1999; Terada
294 et al., 1993) receptors are located on pericytes along the descending vasa recta and regulate contractility
295 at pericyte sites (Crawford et al., 2012). Additionally, endothelin 1 and angiotensin II evoke potent
296 vasoconstriction of the descending vasa recta mainly through endothelin-A (Silldorff et al., 1995) and
297 angiotensin II type 1 (AT1) (Rhinehart et al., 2003) receptors.

298 It has long been known that some pericyte populations in the kidney, especially those in the
299 descending vasa recta, express α -SMA and regulate capillary blood flow (Park et al., 1997; Shaw et al.,
300 2018), presumably via actomyosin-based contractility. A potentially important physiological role for
301 the presence of α -SMA in the descending vasa recta pericytes is the ability of these pericytes to regulate
302 blood flow distribution within the renal medulla (Pallone & Silldorff, 2001; Park et al., 1997). In
303 cerebral, retinal and cardiac pericytes, demonstrating pericyte α -SMA labeling has been difficult, but a
304 more favourable fixative might increase the percentage of cells labelled (Alarcon-Martinez et al., 2018).
305 In agreement with other studies, we observed that α -SMA protein was strongly labelled within the
306 pericytes surrounding the descending vasa recta (Figure 6k-n; see also Park et al., 1997), including in
307 pericytes near ischaemia-evoked blockage sites. Pericyte-specific deletion of α -SMA would allow

308 assessment of whether this is the actin isoform conferring pericyte contractility (cf. Alarcon-Martinez
309 et al. (2019)). Furthermore, ischaemia increased MLC phosphorylation in pericytes (Fig. 6a-j) and led
310 to pericyte-mediated capillary constriction, consistent with actomyosin mediating the contractility of
311 these cells.

312 Rho kinase, a key downstream effector of both endothelin 1 and angiotensin II, inhibits the
313 MLC dephosphorylation required to relax pericytes (Kimura et al., 1996; Maeda et al., 2003), mainly
314 by inhibiting eNOS activity (Versteilen et al., 2006), thus promoting constriction (Hartmann et al.,
315 2021). Rho kinase also promotes actin polymerization (Kutcher & Herman, 2009; Maekawa et al., 1999;
316 W. Zhang et al., 2018). We found that blocking Rho kinase with hydroxyfasudil reduced MLC
317 phosphorylation in pericytes after ischaemia (Figure 6a-j), and reversed ischaemia-evoked pericyte-
318 mediated capillary constriction (hydroxyfasudil increased the capillary diameter specifically at pericyte
319 somata (Figure 4g) in ischaemic animals, implying that the effects of Rho kinase inhibition were on
320 renal pericytes rather than an extra-renal systemic action). This could explain why Rho kinase block
321 reduces acute kidney injury (Kentrup et al., 2011; Prakash et al., 2008; Teraishi et al., 2004; Versteilen
322 et al., 2011; Versteilen et al., 2006), as we have confirmed using kidney injury molecule-1 (Kim-1) as
323 a marker (Figure 7c, d). In addition to inhibiting pericyte-mediated capillary constriction,
324 hydroxyfasudil may also reduce kidney injury by reducing microvascular leukocyte accumulation,
325 possibly by increasing the activity of eNOS (Versteilen et al., 2011; Yamasowa et al., 2005). It will be
326 of interest to assess the efficacy of Rho kinase block for preventing kidney injury after longer periods
327 of ischaemia than the one hour that we employed. In agreement with our findings in kidney pericytes,
328 Rho kinase inhibition can block optogenetically-induced constriction of brain capillaries by pericytes
329 (Hartmann et al., 2021). Taken together, these findings support the concept that ischaemia-evoked
330 capillary constriction reflects renal pericytes generating an actomyosin-dependent contraction, rather
331 than there being a non-specific mechanism of constriction such as pericyte swelling.

332 Hydroxyfasudil is the active metabolite of fasudil, a drug that has been clinically approved in
333 Japan since 1995 for the treatment of vasospasm following subarachnoid hemorrhage (Lingor et al.,
334 2019). Fasudil treatment improves stroke outcome in animal models (Vesterinen et al., 2013) and

335 humans (Shibuya et al., 2005) and our data suggest that it may also be useful for reducing post-
336 ischaemic renal no-reflow and kidney damage.

337 We considered possible non-pericyte explanations for post-ischaemic capillary constriction and
338 block. Post-ischaemic erythrocyte congestion in vasa recta has previously been described (Crislip et al.,
339 2017; Olof et al., 1991) however physically-adhering red blood cells do not physically cause the
340 capillary blockages observed after ischaemia as they were associated with only a small percentage of
341 block sites (Figure 4-figure supplement 1a, b). Thus, red blood cell trapping could be a consequence
342 rather than a cause of the blockages. However, we cannot rule out the possibility that we observed only
343 a small percentage of red blood cells in the capillary lumen because they are more readily displaced
344 during the perfusion with PBS and PFA followed by FITC-albumin in gelatin than with protocols that
345 do not perform transcatheter perfusion or perform it only once (Gaudin et al., 2014; Yemisci et al., 2009).
346 Leukocyte trapping may also contribute to reducing blood flow, but occurs on a longer time scale than
347 we have studied (Kelly et al., 1994; Rabb et al., 1995; Ysebaert et al., 2000). Similarly, although a
348 degradation of the eGCX has been reported after ischaemia (Snoeijs et al., 2010; Song et al., 2018), we
349 found a uniform distribution of the eGCX along the vessel wall, which was not modified after ischaemia
350 (Figure 4-figure supplement 1e-h), thus ruling out a causal association with capillary blockages which
351 are preferentially located near pericytes. The present study demonstrates that pericyte-mediated
352 constrictions of the descending vasa recta and cortical peritubular capillaries contribute to no-reflow
353 and kidney injury at early stages of reperfusion, however we cannot exclude the possibility that other
354 factors, such as inflammation and leukocyte infiltration (Gandolfo et al., 2009; Kelly et al., 1994; Rabb
355 et al., 1995; Ysebaert et al., 2000), or eGCX dysfunction (Bongoni et al., 2019), might also contribute
356 to post-ischaemic microvascular injury at later phases of acute kidney injury. Furthermore, in response
357 to the pericyte-mediated constriction evoked by ischaemia, the DVR may undergo post-ischaemic
358 adaptations, releasing more nitric oxide at 48 hours post-ischaemia which could reduce pericyte
359 constriction at later times after ischaemia than we have studied (Zhang et al., 2018b).

360 The recovery of blood flow in the medulla on renal arterial reperfusion was slower than in the
361 cortex. The regulation of renal medullary blood flow is mainly mediated by vasa recta pericytes,

362 independent of total or cortical blood flow (Pallone & Silldorff, 2001). The need for accurate flow
363 regulation in the relatively hypoxic medulla may account for pericytes on the DVR being much closer
364 together (mean separation $22.9 \pm 0.9 \mu\text{m}$) and with more circumferential processes (Figure 4a-c, Figure
365 4-figure supplement 2b) than for peritubular cortical pericytes (mean separation $41.3 \pm 2.6 \mu\text{m}$) which
366 have mainly longitudinal (strand-like) processes (Figures 5a-c, Figure 4-figure supplement 2a) and this
367 may, in turn, contribute to a greater pericyte-mediated restriction of blood flow after ischaemia in the
368 DVR than in the cortical capillaries. Despite these morphological differences between cortical and
369 medullary pericytes, they showed similar immunoreactivity changes for p-MLC after
370 ischaemia/reperfusion and hydroxyfasudil treatment (Figure 6a-j). Perhaps surprisingly, given our data,
371 in post-cadaveric renal transplants a better outcome has been reported for kidneys with a higher number
372 of pericytes immediately post-transplant (Kwon et al., 2008). This may, however, reflect an aspect of
373 pericyte function other than capillary constriction, such as angiogenesis and maintenance of vessel
374 integrity (Shaw et al., 2018), with these functions failing in transplanted tissue in which pericytes have
375 already died due to ischaemia.

376 In the brain, heart and retina, contractile pericytes on capillaries play a key role in producing a
377 prolonged reduction of blood flow after ischaemia (Hall et al., 2014; O'Farrell et al., 2017; Yemisci et
378 al., 2009). Depending on the type of ischaemic model applied to these organs, collateral vessels may
379 allow some (reduced) blood flow after the onset of ischaemia, which would lead to variable organ
380 damage (Farkas et al., 2007; Liu et al., 2019; Minhas et al., 2012). In contrast, the kidney largely
381 depends on the renal artery to provide a non-anastomotic supply to the glomeruli of each nephro-
382 vascular unit (Evans et al., 2013; Pallone et al., 2012). Medullary hypoxia under normal conditions has
383 been documented in several mammalian species, including humans (Epstein et al., 1982; Leonhardt &
384 Landes, 1963). The medullary partial pressure of oxygen is $\sim 10\text{-}20 \text{ mm Hg}$, contrasting with the partial
385 pressure of oxygen in the cortex, which is $\sim 50 \text{ mm Hg}$ (Brezis, et al., (1994a); Brezis et al., 1991;
386 Brezis, et al., (1994b)). Thus, renal pericytes, especially in the medulla, are likely to be more susceptible
387 to ischaemic injury than in other organs.

388 Rodent models of renal ischaemia can employ bilateral ischaemia or unilateral ischaemia with
389 or without contralateral nephrectomy (Fu et al., 2018). In the present study, unilateral ischaemia without
390 contralateral nephrectomy (which may occur during renal-sparing surgeries) (Hollenbeck et al., 2006;
391 Medina-Rico et al., 2018) was chosen to explore the early mechanisms of ischaemia and reperfusion
392 injury while using the contralateral kidney as a paired control for potential systemic hemodynamic
393 changes that could be triggered during and after the surgical procedure. The presence of an uninjured
394 contralateral kidney reduces animal mortality during the surgical procedure, and thus longer ischaemia
395 times can be used, resulting in more severe and reproducible injury (Fu et al., 2018; Le Clef et al., 2016;
396 Polichnowski et al., 2020; Soranno et al., 2019). Unilateral ischaemia-reperfusion without contralateral
397 nephrectomy is considered a strong model to study the progression from acute renal injury to long-term
398 tubulo-interstitial fibrosis (Fu et al., 2018; Le Clef et al., 2016; Polichnowski et al., 2020; Soranno et
399 al., 2019), but we acknowledge that the model used in the present study may not be similar to some
400 clinical situations where both kidneys are injured, and there are limitations of translatability from all
401 animal models of acute kidney injury to human disease (Fu et al., 2018). A limitation of our study is
402 that all experiments were performed on male rats and mice. Female rats are relatively protected against
403 post-ischaemic renal failure (Lima-Posada et al., 2017; Muller et al., 2002), possibly because in male
404 rats androgens promote ischaemic kidney damage by triggering endothelin-induced vascular
405 constriction (Muller et al., 2002). However, these studies showed that sex did not influence ischaemia
406 repletion-induced injury after 24 hours, but only after 7 days (Lima-Posada et al., 2017; Muller et al.,
407 2002), i.e. on a much longer time scale than we have studied.

408 In the present study, we have shown that pericyte contraction contributes to reducing cortical
409 and medullary blood flow at early stages of reperfusion. This initial pattern could also contribute to the
410 pericyte injury, detachment and capillary rarefaction observed at later stages after ischaemia and
411 reperfusion (Kramann et al., 2017), which lead to further damage to the kidney (Khairoun et al., 2013;
412 Kramann et al., 2017). However, there was no evidence of pericyte detachment during the time frame
413 of the present study. Treatment from the beginning of reperfusion (to mimic a clinically-possible
414 therapeutic approach) with hydroxyfasudil, a Rho kinase inhibitor, increased medullary and cortical

415 blood flow, increased the post-ischaemic diameter of DVR capillaries at pericyte locations, reduced the
416 percentage of DVR capillaries that remained blocked, and reduced kidney injury after renal reperfusion.
417 Presumably the protection of renal blood flow and downstream tissue health would be even greater if
418 hydroxyfasudil could be given before ischaemia was induced (e.g. in situations such as cardiac surgery
419 and kidney transplantation, where renal ischaemia might be anticipated). Thus, pericytes are a novel
420 therapeutic target for reducing no-reflow after renal ischaemia. Acute kidney injury caused by post-
421 ischaemic no-reflow causes significant socio-economic cost. Our identification of pericyte contraction
422 as a therapeutic target for ischaemia-induced acute kidney injury should contribute to the development
423 or re-purposing of drugs that can prevent renal no-reflow.

424

Key Resources Table				
Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
strain, strain background <i>Rattus norvegicus</i> (Sprague Dawley, male)	Rat	UCL Biological Services		
genetic reagent (<i>Mus musculus/spretus</i> , male)	NG2-DsRed mice	doi: 10.1242/dev.004895	JAX 008241	
antibody	anti-NG2 (mouse monoclonal)	AbCam	ab50009	(1:200)
antibody	Anti-Myosin light chain (phospho S20) (rabbit polyclonal)	AbCam	ab5694	(1:100)
antibody	kidney injury molecule-1 (Kim-1) (rabbit polyclonal)	Novus Biologicals	NBP1-76701	(1:100)
antibody	anti-alpha smooth muscle actin (rabbit polyclonal)	AbCam	ab5694	(1:100)
antibody	anti-glycophorin A (mouse monoclonal)	AbCam	ab9520	(1:2000)
antibody	Alexa Fluor 405 goat anti-rabbit (polyclonal)	ThermoFisher	A31556	(1:500)

antibody	Alexa Fluor 555 donkey anti-rabbit (polyclonal)	ThermoFisher	A31572	(1:500)
antibody	Alexa Fluor 555 donkey anti-mouse (polyclonal)	ThermoFisher	A31570	(1:500)
chemical compound, drug	isolectin B ₄ - Alexa Fluor 647	ThermoFisher	I32450	(1:200)
chemical compound, drug	wheat germ agglutinin Alexa Fluor 647 conjugate	ThermoFisher	W32466	200 µl (1 mg/ml)
chemical compound, drug	Hoechst 33342	ThermoFisher	H21492	1 mg/kg in 0.5 ml saline
chemical compound, drug	gelatin	Sigma-Aldrich	G2625	5% in PBS
chemical compound, drug	FITC-albumin	Sigma-Aldrich	A9771	1:200 in 5% gelatin
chemical compound, drug	FITC-albumin	Sigma-Aldrich	A9771	(1 mg in 100 µl; i.v.)
chemical compound, drug	Hydroxyfasudil hydrochloride	Santa Cruz Biotechnology	sc-202176	(3 mg/kg; i.v.)
software, algorithm	<i>MATLAB R2015a</i>	MathWorks, Inc.		in vivo data acquisition
software, algorithm	ImageJ	https://imagej.nih.gov/ij/		image analysis
software, algorithm	GraphPad Prism 6	GraphPad Software, Inc		statistical analysis
other	DAPI stain	Molecular Probes	D1306	200 µl (5 µg/ml)

426

427 **Study approval**

428 Experiments were performed in accordance with European Commission Directive 2010/63/EU
429 and the UK Animals (Scientific Procedures) Act (1986), with approval from the UCL Animal Welfare
430 and Ethical Review Body.

431 **Animal preparation for ischaemia experiments**

432 Due to the high density of kidney tissue, intravital microscopy is limited to superficial regions
433 of the cortex <100 µm deep (Sandoval & Molitoris, 2017). As the renal medulla is inaccessible for in
434 vivo imaging, we used laser Doppler flowmetry to assess blood flow changes of both kidneys or within
435 the cortex and medulla of one kidney simultaneously. Additionally, we used FITC-albumin gelatin
436 perfusion for measuring microvascular network perfusion (O'Farrell et al., 2017) in the renal cortex and
437 medulla, supplemented with high resolution images of individual capillaries to assess the mechanisms
438 underlying blood flow changes.

439 Adult male Sprague-Dawley rats (P40-50), or NG2-dsRed male mice (P100-120) expressing
440 dsRed in pericytes to allow live pericyte imaging, were anesthetized with pentobarbital sodium
441 (induction 60 mg/kg i.p.; maintenance 10-15 mg/kg/h i.v.). The femoral veins were cannulated to
442 administer anesthetic and drugs. Stable kidney perfusion was confirmed using laser Doppler probes
443 (OxyFlo™ Pro 2-channel laser Doppler, Oxford, United Kingdom) to measure blood flow in the
444 contralateral kidney throughout the experiment, and anesthesia was monitored by the absence of a
445 withdrawal response to a paw pinch. Body temperature was maintained at 37.0±0.5°C with a heating
446 pad.

447 **Renal ischaemia and reperfusion**

448 Both kidneys were exposed, and the renal arteries and veins were dissected. Left kidneys were
449 subjected to 60 min ischaemia by renal artery and vein cross-clamp, followed by 30 or 60 min
450 reperfusion. This reperfusion duration was chosen to assess pericyte function soon after starting
451 reperfusion. Right kidneys underwent the same procedures without vessel clamping. Two laser Doppler
452 single-fibre implantable probes of 0.5mm diameter (MSF100NX, Oxford Optronix, Oxford, United
453 Kingdom) measured simultaneously the perfusion of both kidneys (or of the outer medulla and cortex
454 of one kidney). Cortical and outer medullary perfusion were measured with the probe on or 2 mm below

455 the kidney surface, respectively. Successful artery and vein occlusion was confirmed by a sudden fall
456 of laser Doppler signal. Laser Doppler monitoring, which detects the movement of cells in the blood,
457 is a widely used method for studies of microvascular perfusion in experimental and clinical studies and
458 measures the total local microcirculatory blood perfusion in capillaries, arterioles, venules and shunting
459 vessels (Fredriksson et al., 2009; Rajan et al., 2009). Laser Doppler is suitable for monitoring of relative
460 renal microvascular blood flow changes in response to physiological and pharmacological stimuli in
461 rodents (Lu et al., 1993; Vassileva et al., 2003).

462 Endothelial glycocalyx (eGCX) was labelled *in vivo* using wheat germ agglutinin (WGA)
463 Alexa Fluor 647 conjugate (ThermoFisher, W32466, Waltham, MA) injected through the jugular vein
464 (200 μ l, 1 mg/ml) 45 minutes before renal ischaemia/reperfusion (Kutuzov et al., 2018). WGA binds to
465 N-acetyl-D-glucosamine and sialic acid residues of the eGCX. Using ImageJ, WGA fluorescence
466 intensities were measured by drawing regions of interest (ROIs) across capillaries at the mid-points of
467 pericyte somata, and away from the soma in 5 μ m increments on both sides of the pericyte. Capillary
468 diameters were also measured at each position.

469 Hydroxyfasudil hydrochloride, a reversible cell-permeable inhibitor of Rho kinase (Santa Cruz
470 Biotechnology sc-202176, Dallas, TX) which is expected to decrease pericyte contractility (Hartmann
471 et al., 2021; Kutcher et al., 2007) was administered as a bolus (3 mg/kg *i.v.*), immediately on starting
472 reperfusion. This protocol, rather than having the drug present during the ischaemic insult, better
473 mimics a clinical situation where drugs could be given on reperfusion. Control and non-treated
474 ischaemic animals received saline infusion with the same volume.

475 **Animal perfusion and tissue preparation for imaging**

476 After renal ischaemia/reperfusion, animals were overdosed with pentobarbital sodium and
477 transcardially-perfused with phosphate-buffered saline (PBS) (200 ml) followed by 4%
478 paraformaldehyde (PFA, 200 ml) fixative and then 5% gelatin (20ml in PBS Sigma-Aldrich, G2625,
479 Darmstadt, Germany) solution containing FITC-albumin (Sigma-Aldrich, A9771, Darmstadt,
480 Germany), followed by immersion in ice for 30 minutes (adapted from (Blinder et al., 2013)). Kidneys
481 were fixed overnight in 4% PFA, and 150 μ m longitudinal sections made for immunohistochemistry.

482 Rats have ~64 ml of blood per kg bodyweight, thus the FITC-albumin gelatin solution would suffice to
483 fill the total blood volume. The gelatin sets when the body temperature falls and traps FITC-albumin in
484 the perfused vessels; blocked vessels show no penetration of FITC-albumin past the block.

485 **In vivo two-photon imaging**

486 NG2-DsRed mice (P100-120) were anesthetized using urethane (1.55 g/kg i.p., in two doses 15
487 min apart). Anesthesia was confirmed by the absence of a paw pinch withdrawal response. Body
488 temperature was maintained at $36.8 \pm 0.3^\circ\text{C}$. A custom-built plate, attached to the kidney using superglue
489 and agarose created a sealed well filled with phosphate-buffered saline during imaging, when the plate
490 was secured under the objective on a custom-built stage.

491 Peritubular capillary diameter was recorded during renal ischaemia/reperfusion using two-
492 photon microscopy of the intraluminal FITC-albumin (1 mg in 100 μl of saline given intravenously).
493 Two-photon excitation used a Newport-Spectra Physics Mai Tai Ti:Sapphire Laser pulsing at 80 MHz,
494 and a (Zeiss LSM710, Oberkochen, Germany) microscope with a 20 \times water immersion objective (NA
495 1.0). Fluorescence was excited using 920 nm wavelength for DsRed, and 820 nm for FITC-albumin and
496 Hoechst 33342. Mean laser power under the objective was <35 mW. Images were analysed using
497 ImageJ. Vessel diameter was defined using a line drawn across the vessel as the width of the
498 intraluminal dye fluorescence.

499 **Immunohistochemistry**

500 Pericytes were labelled by expression of DsRed under control of the NG2 promoter (in mice), or with
501 antibodies to NG2 (1:200; Abcam ab50009, Cambridge, United Kingdom), α -smooth muscle actin (α -
502 SMA) (1:100; Abcam ab5694, Cambridge, United Kingdom), or myosin light chain (phospho S20,
503 1:100, Abcam ab2480, Cambridge, United Kingdom), and the capillary basement membrane and
504 pericytes were labelled with isolectin B₄-Alexa Fluor 647 (1:200, overnight; Molecular Probes, I32450,
505 Thermo Fisher Scientific, Waltham, MA). Z-stacks of the cortex and outer medulla (frame size
506 640.17x640.17 μm) for cell counting were acquired confocally (Zeiss LSM 700, Oberkochen,
507 Germany). Pericyte intersoma distance was calculated between pairs of pericytes on capillaries within
508 the same imaging plane. Kidney damage was assessed using kidney injury molecule-1 (Kim-1) antibody
509 (1:100, overnight; Novus Biologicals, NBP1-76701, Abingdon, United Kingdom). Red blood cells were

510 labelled with antibody to glycophorin A (1:2000, AbCam ab9520, Cambridge, United Kingdom). Alexa
511 Fluor conjugated secondary antibodies were added overnight (1:500; ThermoFisher, A31572, A31556,
512 A31570, Waltham, MA).

513 **Image analysis**

514 Regions of interest (ROIs) were drawn around the renal cortex and medulla (Fig. 1). The cortex
515 thickness, which ranges from 1.5 mm to 3 mm in rodents, was defined as the distance from the renal
516 surface (capsule) to the base of the medullar pyramid (Andersen et al., 2020; Missbach-Guentner et al.,
517 2018; Nogueira et al., 2016). The FITC-albumin perfusion coupled with image threshold application
518 also helped to visualise the cortical vessels and medullary rays in order to define the corticomedullary
519 boundary. The mean FITC-albumin signal intensity was measured for each ROI using ImageJ. This
520 signal is assumed to provide an approximate measure of the amount of blood perfusing the tissue
521 (conceivably downstream capillary constriction could lead to an upstream dilation and an increased
522 blood volume being detected but, if this did occur, it would lead to an underestimate of the decrease of
523 perfusion occurring). To gain a more accurate assessment of perfusion, we also used the ImageJ macro
524 TubeAnalyst (Advanced Digital Microscopy Core Facility at IRB Barcelona) to measure the
525 microvascular network “skeleton” of the renal cortex and medulla and obtain the total perfused capillary
526 length, the number of perfused capillary segments and the overall perfused microvascular volume
527 fraction (Figure 2b-d). To quantify the percentage of perfused capillaries, we counted the number of
528 filled (with FITC-albumin) and unfilled vessels that crossed a line drawn through the centre of each
529 image perpendicular to the main capillary axis.

530 To assess whether pericytes cause flow blockages, we measured the distance along the capillary
531 from the termination of the FITC-albumin signal to the mid-point of the nearest visible pericyte soma,
532 since in brain most contractile circumferential pericyte processes (which can adjust capillary diameter)
533 are near the pericyte soma (see Figures 4d, 5f, S2 and S3 of Nortley et al., 2019)). Capillary diameters
534 were measured at the block sites where the FITC-albumin signal terminated. We also plotted the
535 diameter of the FITC-albumin labelled capillary lumen as a function of the distance from the pericyte
536 somata to assess whether diameter reduction was a nonspecific effect of ischaemia, or was pericyte-

537 related. A constriction seen specifically at pericyte somata is an unambiguous indication that pericyte
538 contraction is occurring (Nortley et al., 2019). The identification, and direction of flow, of the afferent
539 and efferent arterioles were deduced from tracking in confocal Z-stacks.

540 For quantification of the p-MLC levels in cortical and medullary pericytes, we selected regions
541 of interest (ROIs) over pericytes after applying to maximum intensity projected stack images a lower
542 and upper threshold, which was similar for all experimental groups (typically 50–150 in 8-bit images).
543 Then, we used the ROIs thus selected to measure the mean fluorescence intensity over all the pericytes
544 in each image. The background signal for each stack was obtained by placing a ROI in the parenchyma,
545 away from but close to, the pericytes and the measured background fluorescence signal was subtracted
546 from the mean intensity measured in the pericyte ROIs.

547 **Statistics**

548 Statistical analysis employed Graphpad Prism (San Diego, CA). Data normality was tested with
549 Shapiro-Wilk tests. Normally distributed data were compared using Student's 2-tailed t-tests or
550 ANOVA tests. Data that were not normally distributed were analysed with Mann-Whitney or Kruskal-
551 Wallis tests. *P* values were corrected for multiple comparisons using a procedure equivalent to the
552 Holm-Bonferroni method or Dunn's test (corrected *P* values are significant if they are less than 0.05).

553

554 **Acknowledgments**

555 We thank Jonathan Lezmy, Svetlana Mastitskaya and Thomas Pfeiffer for comments on the
556 manuscript.

557

558 **Competing interests**

559 The authors declare no conflicts of interest.

560

561 **Funding**

562 Supported by a Rosetrees Trust and Stoneygate Trust grant to DA and FF, and equipment
563 funded by the Wellcome Trust and European Research Council.

564

565

566

567 **References**

- 568 Afyouni, N. E., Halili, H., Moslemi, F., Nematbakhsh, M., Talebi, A., Shirdavani, S., & Maleki, M.
569 (2015). Preventive Role of Endothelin Antagonist on Kidney Ischemia: Reperfusion Injury in Male
570 and Female Rats. *Int J Prev Med*, 6, 128. <https://doi.org/10.4103/2008-7802.172549>
- 571 Alarcon-Martinez, L., Yilmaz-Ozcan, S., Yemisci, M., Schallek, J., Kılıç, K., Can, A., . . . Dalkara, T.
572 (2018). Capillary pericytes express α -smooth muscle actin, which requires prevention of
573 filamentous-actin depolymerization for detection. *Elife*, 7. <https://doi.org/10.7554/eLife.34861>
- 574 Alarcon-Martinez, L., Yilmaz-Ozcan, S., Yemisci, M., Schallek, J., Kılıç, K., Villafranca-Baughman,
575 D., . . . Dalkara, T. (2019). Retinal ischemia induces α -SMA-mediated capillary pericyte contraction
576 coincident with perivascular glycogen depletion. *Acta Neuropathol Commun*, 7(1), 134.
577 <https://doi.org/10.1186/s40478-019-0761-z>
- 578 Allred, A. J., Chappell, M. C., Ferrario, C. M., & Diz, D. I. (2000). Differential actions of renal ischemic
579 injury on the intrarenal angiotensin system. *Am J Physiol Renal Physiol*, 279(4), F636-F645.
580 <https://doi.org/10.1152/ajprenal.2000.279.4.F636>
- 581 Amin, R. P., Vickers, A. E., Sistare, F., Thompson, K. L., Roman, R. J., Lawton, M., . . . Afshari, C. A.
582 (2004). Identification of putative gene based markers of renal toxicity. *Environ Health Perspect*,
583 112(4), 465-479. <https://doi.org/10.1289/ehp.6683>
- 584 Andersen, S. B., Taghavi, I., Hoyos, C. A. V., Sjøgaard, S. B., Gran, F., Lönn, L., . . . Sørensen, C. M.
585 (2020). Super-Resolution Imaging with Ultrasound for Visualization of the Renal Microvasculature
586 in Rats Before and After Renal Ischemia: A Pilot Study. *Diagnostics (Basel)*, 10(11).
587 <https://doi.org/10.3390/diagnostics10110862>
- 588 Blinder, P., Tsai, P. S., Kaufhold, J. P., Knutsen, P. M., Suhl, H., & Kleinfeld, D. (2013). The cortical
589 angiome: an interconnected vascular network with noncolumnar patterns of blood flow. *Nat*
590 *Neurosci*, 16(7), 889-897. <https://doi.org/10.1038/nn.3426>
- 591 Boer, W. H., Braam, B., Fransen, R., Boer, P., & Koomans, H. A. (1997). Effects of reduced renal
592 perfusion pressure and acute volume expansion on proximal tubule and whole kidney angiotensin II
593 content in the rat. *Kidney Int*, 51(1), 44-49. <https://doi.org/10.1038/ki.1997.6>

594 Bongoni, A. K., Lu, B., McRae, J. L., Salvaris, E. J., Toonen, E. J. M., Vikstrom, I., . . . Cowan, P. J.
595 (2019). Complement-mediated Damage to the Glycocalyx Plays a Role in Renal Ischemia-
596 reperfusion Injury in Mice. *Transplant Direct*, 5(4), e341.
597 <https://doi.org/10.1097/TXD.0000000000000881>

598 Bonventre, J. V., & Weinberg, J. M. (2003). Recent advances in the pathophysiology of ischemic acute
599 renal failure. *J Am Soc Nephrol*, 14(8), 2199-2210.
600 <https://doi.org/10.1097/01.asn.0000079785.13922.f6>

601 Brezis, M., Agmon, Y., & Epstein, F. H. (1994a). Determinants of intrarenal oxygenation. I. Effects of
602 diuretics. *Am J Physiol*, 267(6 Pt 2), F1059-1062.
603 <https://doi.org/10.1152/ajprenal.1994.267.6.F1059>

604 Brezis, M., Heyman, S. N., Dinour, D., Epstein, F. H., & Rosen, S. (1991). Role of nitric oxide in renal
605 medullary oxygenation. Studies in isolated and intact rat kidneys. *J Clin Invest*, 88(2), 390-395.
606 <https://doi.org/10.1172/jci115316>

607 Brezis, M., Heyman, S. N., & Epstein, F. H. (1994b). Determinants of intrarenal oxygenation. II.
608 Hemodynamic effects. *Am J Physiol*, 267(6 Pt 2), F1063-1068.
609 <https://doi.org/10.1152/ajprenal.1994.267.6.F1063>

610 Conesa, E. L., Valero, F., Nadal, J. C., Fenoy, F. J., Lopez, B., Arregui, B., & Salom, M. G. (2001). N-
611 acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. *Am J Physiol Regul*
612 *Integr Comp Physiol*, 281(3), R730-R737. <https://doi.org/10.1152/ajpregu.2001.281.3.R730>

613 Crawford, C., Kennedy-Lydon, T., Sprott, C., Desai, T., Sawbridge, L., Munday, J., . . . Peppiatt-
614 Wildman, C. M. (2012). An intact kidney slice model to investigate vasa recta properties and
615 function in situ. *Nephron Physiol*, 120(3), p17-31. <https://doi.org/10.1159/000339110>

616 Crislip, G. R., O'Connor, P. M., Wei, Q., & Sullivan, J. C. (2017). Vasa recta pericyte density is
617 negatively associated with vascular congestion in the renal medulla following ischemia reperfusion
618 in rats. *Am J Physiol Renal Physiol*, 313(5), F1097-F1105.
619 <https://doi.org/10.1152/ajprenal.00261.2017>

620 Cristol, J. P., Thiemermann, C., Guérin, M. C., Torreilles, J., & de Paulet, A. C. (1996). L-Arginine
621 infusion after ischaemia-reperfusion of rat kidney enhances lipid peroxidation. *J Lipid Mediat Cell*
622 *Signal*, 13(1), 9-17. [https://doi.org/10.1016/0929-7855\(95\)00010-0](https://doi.org/10.1016/0929-7855(95)00010-0)

623 da Silveira, K. D., Pompermayer Bosco, K. S., Diniz, L. R., Carmona, A. K., Cassali, G. D., Bruna-
624 Romero, O., . . . Ribeiro Vieira, M. A. (2010). ACE2-angiotensin-(1-7)-Mas axis in renal
625 ischaemia/reperfusion injury in rats. *Clin Sci (Lond)*, 119(9), 385-394.
626 <https://doi.org/10.1042/cs20090554>

627 Dunn, K. W., Sutton, T. A., & Sandoval, R. M. (2018). Live-Animal Imaging of Renal Function by
628 Multiphoton Microscopy. *Curr Protoc Cytom*, 83, 12.19.11-12.19.25.
629 <https://doi.org/10.1002/cpcy.32>

630 Durham, J. T., Surks, H. K., Dulmovits, B. M., & Herman, I. M. (2014). Pericyte contractility controls
631 endothelial cell cycle progression and sprouting: insights into angiogenic switch mechanics. *Am J*
632 *Physiol Cell Physiol*, 307(9), C878-892. <https://doi.org/10.1152/ajpcell.00185.2014>

633 Epstein, F. H., Balaban, R. S., & Ross, B. D. (1982). Redox state of cytochrome aa3 in isolated perfused
634 rat kidney. *Am J Physiol*, 243(4), F356-363. <https://doi.org/10.1152/ajprenal.1982.243.4.F356>

635 Evans, R. G., Ince, C., Joles, J. A., Smith, D. W., May, C. N., O'Connor, P. M., & Gardiner, B. S.
636 (2013). Haemodynamic influences on kidney oxygenation: clinical implications of integrative
637 physiology. *Clin Exp Pharmacol Physiol*, 40(2), 106-122. <https://doi.org/10.1111/1440-1681.12031>

638 Farkas, E., Luiten, P. G., & Bari, F. (2007). Permanent, bilateral common carotid artery occlusion in
639 the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. *Brain Res*
640 *Rev*, 54(1), 162-180. <https://doi.org/10.1016/j.brainresrev.2007.01.003>

641 Fredriksson, I., Larsson, M., & Stromberg, T. (2009). Measurement depth and volume in laser Doppler
642 flowmetry. *Microvasc Res*, 78(1), 4-13. <https://doi.org/10.1016/j.mvr.2009.02.008>

643 Fu, Y., Tang, C., Cai, J., Chen, G., Zhang, D., & Dong, Z. (2018). Rodent models of AKI-CKD
644 transition. *Am J Physiol Renal Physiol*, 315(4), F1098-F1106.
645 <https://doi.org/10.1152/ajprenal.00199.2018>

646 Gameiro, J., Agapito Fonseca, J., Jorge, S., & Lopes, J. A. (2018). Acute Kidney Injury Definition and
647 Diagnosis: A Narrative Review. *J Clin Med*, 7(10). <https://doi.org/10.3390/jcm7100307>

648 Gandolfo, M. T., Jang, H. R., Bagnasco, S. M., Ko, G. J., Agreda, P., Satpute, S. R., . . . Rabb, H.
649 (2009). Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. *Kidney Int*,
650 76(7), 717-729. <https://doi.org/10.1038/ki.2009.259>

651 Gaudin, A., Yemisci, M., Eroglu, H., Lepetre-Mouelhi, S., Turkoglu, O. F., Dönmez-Demir, B., . . .
652 Couvreur, P. (2014). Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and
653 spinal cord injury. *Nat Nanotechnol*, 9(12), 1054-1062. <https://doi.org/10.1038/nnano.2014.274>

654 Hall, C. N., Reynell, C., Gesslein, B., Hamilton, N. B., Mishra, A., Sutherland, B. A., . . . Attwell, D.
655 (2014). Capillary pericytes regulate cerebral blood flow in health and disease. *Nature*, 508(7494),
656 55-60. <https://doi.org/10.1038/nature13165>

657 Hartmann, D. A., Berthiaume, A. A., Grant, R. I., Harrill, S. A., Koski, T., Tieu, T., . . . Shih, A. Y.
658 (2021). Brain capillary pericytes exert a substantial but slow influence on blood flow. *Nat Neurosci*,
659 24(5), 633-645. <https://doi.org/10.1038/s41593-020-00793-2>

660 Hirunpattarasilp, C., Attwell, D., & Freitas, F. (2019). The role of pericytes in brain disorders: from the
661 periphery to the brain. *J Neurochem*, 150(6), 648-665. <https://doi.org/10.1111/jnc.14725>

662 Hollenbeck, B. K., Taub, D. A., Miller, D. C., Dunn, R. L., & Wei, J. T. (2006). National utilization
663 trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? *Urology*, 67(2),
664 254-259. <https://doi.org/10.1016/j.urology.2005.08.050>

665 Homma, K., Hayashi, K., Wakino, S., Tokuyama, H., Kanda, T., Tatematsu, S., . . . Itoh, H. (2014).
666 Rho-kinase contributes to pressure-induced constriction of renal microvessels. *Keio J Med*, 63(1),
667 1-12. <https://www.ncbi.nlm.nih.gov/pubmed/24429483>

668 Hoste, E. A. J., Kellum, J. A., Selby, N. M., Zarbock, A., Palevsky, P. M., Bagshaw, S. M., . . . Chawla,
669 L. S. (2018). Global epidemiology and outcomes of acute kidney injury. *Nat Rev Nephrol*, 14(10),
670 607-625. <https://doi.org/10.1038/s41581-018-0052-0>

671 Ichimura, T., Bonventre, J. V., Bailly, V., Wei, H., Hession, C. A., Cate, R. L., & Sanicola, M. (1998).
672 Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel

673 immunoglobulin domain, is up-regulated in renal cells after injury. *J Biol Chem*, 273(7), 4135-4142.
674 <https://doi.org/10.1074/jbc.273.7.4135>

675 Jahani, V., Kavousi, A., Mehri, S., & Karimi, G. (2018). Rho kinase, a potential target in the treatment
676 of metabolic syndrome. *Biomed Pharmacother*, 106, 1024-1030.
677 <https://doi.org/10.1016/j.biopha.2018.07.060>

678 Jones, N. K., Stewart, K., Czopek, A., Menzies, R. I., Thomson, A., Moran, C. M., . . . Bailey, M. A.
679 (2020). Endothelin-1 Mediates the Systemic and Renal Hemodynamic Effects of GPR81 Activation.
680 *Hypertension*, 75(5), 1213-1222. <https://doi.org/10.1161/HYPERTENSIONAHA.119.14308>

681 Kelly, K. J., Williams, W. W., Jr., Colvin, R. B., & Bonventre, J. V. (1994). Antibody to intercellular
682 adhesion molecule 1 protects the kidney against ischemic injury. *Proc Natl Acad Sci U S A*, 91(2),
683 812-816. <https://doi.org/10.1073/pnas.91.2.812>

684 Kentrup, D., Reuter, S., Schnockel, U., Grabner, A., Edemir, B., Pavenstadt, H., . . . Bussemaker, E.
685 (2011). Hydroxyfasudil-mediated inhibition of ROCK1 and ROCK2 improves kidney function in
686 rat renal acute ischemia-reperfusion injury. *PLoS One*, 6(10), e26419.
687 <https://doi.org/10.1371/journal.pone.0026419>

688 Khairoun, M., van der Pol, P., de Vries, D. K., Lievers, E., Schlagwein, N., de Boer, H. C., . . . Reinders,
689 M. E. (2013). Renal ischemia-reperfusion induces a dysbalance of angiotensins, accompanied by
690 proliferation of pericytes and fibrosis. *Am J Physiol Renal Physiol*, 305(6), F901-F910.
691 <https://doi.org/10.1152/ajprenal.00542.2012>

692 Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., . . . Kaibuchi, K. (1996).
693 Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science*,
694 273(5272), 245-248. <https://doi.org/10.1126/science.273.5272.245>

695 Kramann, R., Wongboonsin, J., Chang-Panesso, M., Machado, F. G., & Humphreys, B. D. (2017).
696 Gli1(+) Pericyte Loss Induces Capillary Rarefaction and Proximal Tubular Injury. *J Am Soc*
697 *Nephrol*, 28(3), 776-784. <https://doi.org/10.1681/asn.2016030297>

698 Kureli, G., Yilmaz-Ozcan, S., Erdener, S. E., Donmez-Demir, B., Yemisci, M., Karatas, H., & Dalkara,
699 T. (2020). F-actin polymerization contributes to pericyte contractility in retinal capillaries. *Exp*
700 *Neurol*, 332, 113392. <https://doi.org/10.1016/j.expneurol.2020.113392>

701 Kushiyama, T., Oda, T., Yamamoto, K., Higashi, K., Watanabe, A., Takechi, H., . . . Kumagai, H.
702 (2013). Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease. *Am J*
703 *Physiol Renal Physiol*, 304(11), F1325-F1334. <https://doi.org/10.1152/ajprenal.00447.2012>

704 Kutcher, M. E., & Herman, I. M. (2009). The pericyte: cellular regulator of microvascular blood flow.
705 *Microvasc Res*, 77(3), 235-246. <https://doi.org/10.1016/j.mvr.2009.01.007>

706 Kutcher, M. E., Kolyada, A. Y., Surks, H. K., & Herman, I. M. (2007). Pericyte Rho GTPase mediates
707 both pericyte contractile phenotype and capillary endothelial growth state. *Am J Pathol*, 171(2), 693-
708 701. <https://doi.org/10.2353/ajpath.2007.070102>

709 Kutuzov, N., Flyvbjerg, H., & Lauritzen, M. (2018). Contributions of the glycocalyx, endothelium, and
710 extravascular compartment to the blood-brain barrier. *Proc Natl Acad Sci U S A*, 115(40), E9429-
711 e9438. <https://doi.org/10.1073/pnas.1802155115>

712 Kwon, O., Hong, S. M., Sutton, T. A., & Temm, C. J. (2008). Preservation of peritubular capillary
713 endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute
714 kidney injury. *Am J Physiol Renal Physiol*, 295(2), F351-F359.
715 <https://doi.org/10.1152/ajprenal.90276.2008>

716 Lameire, N., Van Biesen, W., & Vanholder, R. (2006). The changing epidemiology of acute renal
717 failure. *Nat Clin Pract Nephrol*, 2(7), 364-377. <https://doi.org/10.1038/ncpneph0218>

718 Lameire, N., & Vanholder, R. (2001). Pathophysiologic features and prevention of human and
719 experimental acute tubular necrosis. *J Am Soc Nephrol*, 12 Suppl 17, S20-S32.
720 <https://www.ncbi.nlm.nih.gov/pubmed/11251028>

721 Le Clef, N., Verhulst, A., D'Haese, P. C., & Vervaet, B. A. (2016). Unilateral Renal Ischemia-
722 Reperfusion as a Robust Model for Acute to Chronic Kidney Injury in Mice. *PLoS One*, 11(3),
723 e0152153. <https://doi.org/10.1371/journal.pone.0152153>

724 Lee, T. M., Chung, T. H., Lin, S. Z., & Chang, N. C. (2014). Endothelin receptor blockade ameliorates
725 renal injury by inhibition of RhoA/Rho-kinase signalling in deoxycorticosterone acetate-salt
726 hypertensive rats. *J Hypertens*, *32*(4), 795-805. <https://doi.org/10.1097/HJH.0000000000000092>

727 Leonhardt, K. O., & Landes, R. R. (1963). Oxygen tension of the urine and renal structures. Preliminary
728 report of clinical findings. *N Engl J Med*, *269*, 115-121.
729 <https://doi.org/10.1056/nejm196307182690301>

730 Lima-Posada, I., Portas-Cortes, C., Perez-Villalva, R., Fontana, F., Rodriguez-Romo, R., Prieto, R., . .
731 . Bobadilla, N. A. (2017). Gender Differences in the Acute Kidney Injury to Chronic Kidney Disease
732 Transition. *Sci Rep*, *7*(1), 12270. <https://doi.org/10.1038/s41598-017-09630-2>

733 Lingor, P., Weber, M., Camu, W., Friede, T., Hilgers, R., Leha, A., . . . Investigators, R.-A. (2019).
734 ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of
735 Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic
736 Lateral Sclerosis. *Front Neurol*, *10*, 293. <https://doi.org/10.3389/fneur.2019.00293>

737 Liu, X., Dong, H., Huang, B., Miao, H., Xu, Z., Yuan, Y., . . . Zhang, Z. (2019). Native Coronary
738 Collateral Microcirculation Reserve in Rat Hearts. *J Am Heart Assoc*, *8*(5), e011220.
739 <https://doi.org/10.1161/jaha.118.011220>

740 Lu, S., Mattson, D. L., Roman, R. J., Becker, C. G., & Cowley, A. W., Jr. (1993). Assessment of changes
741 in intrarenal blood flow in conscious rats using laser-Doppler flowmetry. *Am J Physiol*, *264*(6 Pt 2),
742 F956-962. <https://doi.org/10.1152/ajprenal.1993.264.6.F956>

743 Maeda, Y., Hirano, K., Nishimura, J., Sasaki, T., & Kanaide, H. (2003). Rho-kinase inhibitor inhibits
744 both myosin phosphorylation-dependent and -independent enhancement of myofilament Ca²⁺
745 sensitivity in the bovine middle cerebral artery. *Br J Pharmacol*, *140*(5), 871-880.
746 <https://doi.org/10.1038/sj.bjp.0705487>

747 Maekawa, M., Ishizaki, T., Boku, S., Watanabe, N., Fujita, A., Iwamatsu, A., . . . Narumiya, S. (1999).
748 Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase.
749 *Science*, *285*(5429), 895-898. <https://doi.org/10.1126/science.285.5429.895>

750 McCurley, A., Alimperti, S., Campos-Bilderback, S. B., Sandoval, R. M., Calvino, J. E., Reynolds, T.
751 L., . . . Crackower, M. A. (2017). Inhibition of alphavbeta5 Integrin Attenuates Vascular
752 Permeability and Protects against Renal Ischemia-Reperfusion Injury. *J Am Soc Nephrol*, 28(6),
753 1741-1752. <https://doi.org/10.1681/ASN.2016020200>

754 Medina-Rico, M., Ramos, H. L., Lobo, M., Romo, J., & Prada, J. G. (2018). Epidemiology of renal
755 cancer in developing countries: Review of the literature. *Can Urol Assoc J*, 12(3), E154-E162.
756 <https://doi.org/10.5489/cuaj.4464>

757 Mehta, R. L., Burdmann, E. A., Cerda, J., Feehally, J., Finkelstein, F., Garcia-Garcia, G., . . . Remuzzi,
758 G. (2016). Recognition and management of acute kidney injury in the International Society of
759 Nephrology Oby25 Global Snapshot: a multinational cross-sectional study. *Lancet*, 387(10032),
760 2017-2025. [https://doi.org/10.1016/S0140-6736\(16\)30240-9](https://doi.org/10.1016/S0140-6736(16)30240-9)

761 Minhas, G., Morishita, R., & Anand, A. (2012). Preclinical models to investigate retinal ischemia:
762 advances and drawbacks. *Front Neurol*, 3, 75. <https://doi.org/10.3389/fneur.2012.00075>

763 Missbach-Guentner, J., Pinkert-Leetsch, D., Dullin, C., Ufartes, R., Hornung, D., Tampe, B., . . . Alves,
764 F. (2018). 3D virtual histology of murine kidneys -high resolution visualization of pathological
765 alterations by micro computed tomography. *Sci Rep*, 8(1), 1407. [https://doi.org/10.1038/s41598-](https://doi.org/10.1038/s41598-018-19773-5)
766 [018-19773-5](https://doi.org/10.1038/s41598-018-19773-5)

767 Miyata, N., Park, F., Li, X. F., & Cowley, A. W., Jr. (1999). Distribution of angiotensin AT1 and AT2
768 receptor subtypes in the rat kidney. *Am J Physiol*, 277(3), F437-F446.
769 <https://doi.org/10.1152/ajprenal.1999.277.3.F437>

770 Muller, V., Losonczy, G., Heemann, U., Vannay, A., Fekete, A., Reusz, G., . . . Szabo, A. J. (2002).
771 Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. *Kidney*
772 *Int*, 62(4), 1364-1371. <https://doi.org/10.1111/j.1523-1755.2002.kid590.x>

773 Nijveldt, R. J., Prins, H. A., van Kemenade, F. J., Teerlink, T., van Lambalgen, A. A., Boelens, P. G., .
774 . . van Leeuwen, P. A. (2001). Low arginine plasma levels do not aggravate renal blood flow after
775 experimental renal ischaemia/reperfusion. *Eur J Vasc Endovasc Surg*, 22(3), 232-239.
776 <https://doi.org/10.1053/ejvs.2001.1444>

777 Nogueira, A., Rocha, A. F., Ginja, M., Oliveira, P. A., & Pires, M. J. (2016). Ultrasonographic
778 Evaluation of the Kidney in 5/6 Nephrectomized Rats: Correlation with Biochemical and
779 Histopathological Findings. *In Vivo*, *30*(6), 829-834. <https://doi.org/10.21873/invivo.11001>

780 Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., . . . Attwell, D.
781 (2019). Amyloid beta oligomers constrict human capillaries in Alzheimer's disease via signaling to
782 pericytes. *Science*, *365*(6450). <https://doi.org/10.1126/science.aav9518>

783 O'Farrell, F. M., Mastitskaya, S., Hammond-Haley, M., Freitas, F., Wah, W. R., & Attwell, D. (2017).
784 Capillary pericytes mediate coronary no-reflow after myocardial ischaemia. *Elife*, *6*.
785 <https://doi.org/10.7554/eLife.29280>

786 Olof, P., Hellberg, A., Kallskog, O., & Wolgast, M. (1991). Red cell trapping and postischemic renal
787 blood flow. Differences between the cortex, outer and inner medulla. *Kidney Int*, *40*(4), 625-631.
788 <https://doi.org/10.1038/ki.1991.254>

789 Pallone, T. L., Edwards, A., & Mattson, D. L. (2012). Renal medullary circulation. *Compr Physiol*,
790 *2*(1), 97-140. <https://doi.org/10.1002/cphy.c100036>

791 Pallone, T. L., & Sillardorff, E. P. (2001). Pericyte regulation of renal medullary blood flow. *Exp Nephrol*,
792 *9*(3), 165-170. <https://doi.org/10.1159/000052608>

793 Park, F., Mattson, D. L., Roberts, L. A., & Cowley, A. W., Jr. (1997). Evidence for the presence of
794 smooth muscle alpha-actin within pericytes of the renal medulla. *Am J Physiol*, *273*(5), R1742-
795 R1748. <https://doi.org/10.1152/ajpregu.1997.273.5.R1742>

796 Pearson, J. T., Jenkins, M. J., Edgley, A. J., Sonobe, T., Joshi, M., Waddingham, M. T., . . . Shirai, M.
797 (2013). Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic
798 microcirculation. *Cardiovasc Diabetol*, *12*, 111. <https://doi.org/10.1186/1475-2840-12-111>

799 Peng, F., Wu, D., Gao, B., Ingram, A. J., Zhang, B., Chorneyko, K., . . . Krepinsky, J. C. (2008).
800 RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. *Diabetes*, *57*(6), 1683-
801 1692. <https://doi.org/10.2337/db07-1149>

802 Polichnowski, A. J., Griffin, K. A., Licea-Vargas, H., Lan, R., Picken, M. M., Long, J., . . . Bidani, A.
803 K. (2020). Pathophysiology of unilateral ischemia-reperfusion injury: importance of renal

804 counterbalance and implications for the AKI-CKD transition. *Am J Physiol Renal Physiol*, 318(5),
805 F1086-f1099. <https://doi.org/10.1152/ajprenal.00590.2019>

806 Ponce, D., & Balbi, A. (2016). Acute kidney injury: risk factors and management challenges in
807 developing countries. *Int J Nephrol Renovasc Dis*, 9, 193-200. <https://doi.org/10.2147/ijnrd.s104209>

808 Prakash, J., de Borst, M. H., Lacombe, M., Opdam, F., Klok, P. A., van Goor, H., . . . Kok, R. J. (2008).
809 Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. *J Am Soc Nephrol*,
810 19(11), 2086-2097. <https://doi.org/10.1681/ASN.2007070794>

811 Rabb, H., Mendiola, C. C., Saba, S. R., Dietz, J. R., Smith, C. W., Bonventre, J. V., & Ramirez, G.
812 (1995). Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury. *Biochem*
813 *Biophys Res Commun*, 211(1), 67-73. <https://doi.org/10.1006/bbrc.1995.1779>

814 Rajan, V., Varghese, B., van Leeuwen, T. G., & Steenbergen, W. (2009). Review of methodological
815 developments in laser Doppler flowmetry. *Lasers Med Sci*, 24(2), 269-283.
816 <https://doi.org/10.1007/s10103-007-0524-0>

817 Ramaswamy, D., Corrigan, G., Polhemus, C., Boothroyd, D., Scandling, J., Sommer, F. G., . . . Myers,
818 B. D. (2002). Maintenance and recovery stages of postischemic acute renal failure in humans. *Am J*
819 *Physiol Renal Physiol*, 282(2), F271-280. <https://doi.org/10.1152/ajprenal.0068.2001>

820 Regner, K. R., Zuk, A., Van Why, S. K., Shames, B. D., Ryan, R. P., Falck, J. R., . . . Roman, R. J.
821 (2009). Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury.
822 *Kidney Int*, 75(5), 511-517. <https://doi.org/10.1038/ki.2008.600>

823 Rhinehart, K., Handelsman, C. A., Silldorff, E. P., & Pallone, T. L. (2003). ANG II AT2 receptor
824 modulates AT1 receptor-mediated descending vasa recta endothelial Ca²⁺ signaling. *Am J Physiol*
825 *Heart Circ Physiol*, 284(3), H779-789. <https://doi.org/10.1152/ajpheart.00317.2002>

826 Riddick, N., Ohtani, K., & Surks, H. K. (2008). Targeting by myosin phosphatase-RhoA interacting
827 protein mediates RhoA/ROCK regulation of myosin phosphatase. *J Cell Biochem*, 103(4), 1158-
828 1170. <https://doi.org/10.1002/jcb.21488>

829 Ronco, C., Reis, T., & Husain-Syed, F. (2020). Management of acute kidney injury in patients with
830 COVID-19. *Lancet Respir Med*. [https://doi.org/10.1016/S2213-2600\(20\)30229-0](https://doi.org/10.1016/S2213-2600(20)30229-0)

831 Rupérez, M., Sánchez-López, E., Blanco-Colio, L. M., Esteban, V., Rodríguez-Vita, J., Plaza, J. J., . . .
832 Ruiz-Ortega, M. (2005). The Rho-kinase pathway regulates angiotensin II-induced renal damage.
833 *Kidney Int Suppl*(99), S39-45. <https://doi.org/10.1111/j.1523-1755.2005.09908.x>

834 Sanchez-Pozos, K., Barrera-Chimal, J., Garzon-Muvdi, J., Perez-Villalva, R., Rodriguez-Romo, R.,
835 Cruz, C., . . . Bobadilla, N. A. (2012). Recovery from ischemic acute kidney injury by spironolactone
836 administration. *Nephrol Dial Transplant*, 27(8), 3160-3169. <https://doi.org/10.1093/ndt/gfs014>

837 Sandoval, R. M., & Molitoris, B. A. (2017). Intravital multiphoton microscopy as a tool for studying
838 renal physiology and pathophysiology. *Methods*, 128, 20-32.
839 <https://doi.org/10.1016/j.ymeth.2017.07.014>

840 Shaw, I., Rider, S., Mullins, J., Hughes, J., & Péault, B. (2018). Pericytes in the renal vasculature: roles
841 in health and disease. *Nat Rev Nephrol*, 14(8), 521-534. <https://doi.org/10.1038/s41581-018-0032-4>

842 Shibuya, M., Hirai, S., Seto, M., Satoh, S., & Ohtomo, E. (2005). Effects of fasudil in acute ischemic
843 stroke: results of a prospective placebo-controlled double-blind trial. *J Neurol Sci*, 238(1-2), 31-39.
844 <https://doi.org/10.1016/j.jns.2005.06.003>

845 Shimokawa, H., & Rashid, M. (2007). Development of Rho-kinase inhibitors for cardiovascular
846 medicine. *Trends Pharmacol Sci*, 28(6), 296-302. <https://doi.org/10.1016/j.tips.2007.04.006>

847 Sillardorff, E. P., Yang, S., & Pallone, T. L. (1995). Prostaglandin E2 abrogates endothelin-induced
848 vasoconstriction in renal outer medullary descending vasa recta of the rat. *J Clin Invest*, 95(6), 2734-
849 2740. <https://doi.org/10.1172/jci117976>

850 Snoeijs, M. G., Vink, H., Voesten, N., Christiaans, M. H., Daemen, J. W., Peppelenbosch, A. G., . . .
851 van Heurn, L. W. (2010). Acute ischemic injury to the renal microvasculature in human kidney
852 transplantation. *Am J Physiol Renal Physiol*, 299(5), F1134-F1140.
853 <https://doi.org/10.1152/ajprenal.00158.2010>

854 Soga, J., Noma, K., Hata, T., Hidaka, T., Fujii, Y., Idei, N., . . . Higashi, Y. (2011). Rho-associated
855 kinase activity, endothelial function, and cardiovascular risk factors. *Arterioscler Thromb Vasc Biol*,
856 31(10), 2353-2359. <https://doi.org/10.1161/atvbaha.111.227892>

857 Song, J. W., Zullo, J., Lipphardt, M., Dragovich, M., Zhang, F. X., Fu, B., & Goligorsky, M. S. (2018).
858 Endothelial glycocalyx-the battleground for complications of sepsis and kidney injury. *Nephrol Dial*
859 *Transplant*, 33(2), 203-211. <https://doi.org/10.1093/ndt/gfx076>

860 Soranno, D. E., Gil, H. W., Kirkbride-Romeo, L., Altmann, C., Montford, J. R., Yang, H., . . . Faubel,
861 S. (2019). Matching Human Unilateral AKI, a Reverse Translational Approach to Investigate
862 Kidney Recovery after Ischemia. *J Am Soc Nephrol*, 30(6), 990-1005.
863 <https://doi.org/10.1681/ASN.2018080808>

864 Sutton, T. A., Fisher, C. J., & Molitoris, B. A. (2002). Microvascular endothelial injury and dysfunction
865 during ischemic acute renal failure. *Kidney Int*, 62(5), 1539-1549. [https://doi.org/10.1046/j.1523-](https://doi.org/10.1046/j.1523-1755.2002.00631.x)
866 [1755.2002.00631.x](https://doi.org/10.1046/j.1523-1755.2002.00631.x)

867 Terada, Y., Tomita, K., Nonoguchi, H., & Marumo, F. (1993). PCR localization of angiotensin II
868 receptor and angiotensinogen mRNAs in rat kidney. *Kidney Int*, 43(6), 1251-1259.
869 <https://doi.org/10.1038/ki.1993.177>

870 Teraishi, K., Kurata, H., Nakajima, A., Takaoka, M., & Matsumura, Y. (2004). Preventive effect of Y-
871 27632, a selective Rho-kinase inhibitor, on ischemia/reperfusion-induced acute renal failure in rats.
872 *Eur J Pharmacol*, 505(1-3), 205-211. <https://doi.org/10.1016/j.ejphar.2004.10.040>

873 Vaidya, V. S., Ozer, J. S., Dieterle, F., Collings, F. B., Ramirez, V., Troth, S., . . . Bonventre, J. V.
874 (2010). Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical
875 biomarker qualification studies. *Nat Biotechnol*, 28(5), 478-485. <https://doi.org/10.1038/nbt.1623>

876 Vassileva, I., Mountain, C., & Pollock, D. M. (2003). Functional role of ETB receptors in the renal
877 medulla. *Hypertension*, 41(6), 1359-1363. <https://doi.org/10.1161/01.hyp.0000070958.39174.7e>

878 Versteilen, A. M., Blaauw, N., Di Maggio, F., Groeneveld, A. B., Sipkema, P., Musters, R. J., &
879 Tangelder, G. J. (2011). Rho-Kinase inhibition reduces early microvascular leukocyte accumulation
880 in the rat kidney following ischaemia-reperfusion injury: roles of nitric oxide and blood flow.
881 *Nephron Exp Nephrol*, 118(4), e79-86. <https://doi.org/10.1159/000322605>

882 Versteilen, A. M., Korstjens, I. J., Musters, R. J., Groeneveld, A. B., & Sipkema, P. (2006). Rho kinase
883 regulates renal blood flow by modulating eNOS activity in ischemia-reperfusion of the rat kidney.
884 *Am J Physiol Renal Physiol*, 291(3), F606-F611. <https://doi.org/10.1152/ajprenal.00434.2005>

885 Vesterinen, H. M., Currie, G. L., Carter, S., Mee, S., Watzlawick, R., Egan, K. J., . . . Sena, E. S. (2013).
886 Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in
887 animal models of ischaemic stroke. *Syst Rev*, 2, 33. <https://doi.org/10.1186/2046-4053-2-33>

888 Wang, Y., Zheng, X. R., Riddick, N., Bryden, M., Baur, W., Zhang, X., & Surks, H. K. (2009). ROCK
889 isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. *Circ*
890 *Res*, 104(4), 531-540. <https://doi.org/10.1161/CIRCRESAHA.108.188524>

891 Wei, J., Song, J., Jiang, S., Zhang, G., Wheeler, D., Zhang, J., . . . Liu, R. (2017). Role of intratubular
892 pressure during the ischemic phase in acute kidney injury. *Am J Physiol Renal Physiol*, 312(6),
893 F1158-F1165. <https://doi.org/10.1152/ajprenal.00527.2016>

894 Wendel, M., Knels, L., Kummer, W., & Koch, T. (2006). Distribution of endothelin receptor subtypes
895 ETA and ETB in the rat kidney. *J Histochem Cytochem*, 54(11), 1193-1203.
896 <https://doi.org/10.1369/jhc.5A6888.2006>

897 Wilhelm, S. M., Simonson, M. S., Robinson, A. V., Stowe, N. T., & Schulak, J. A. (1999). Endothelin
898 up-regulation and localization following renal ischemia and reperfusion. *Kidney Int*, 55(3), 1011-
899 1018. <https://doi.org/10.1046/j.1523-1755.1999.0550031011.x>

900 Yamamoto, T., Tada, T., Brodsky, S. V., Tanaka, H., Noiri, E., Kajiya, F., & Goligorsky, M. S. (2002).
901 Intravital videomicroscopy of peritubular capillaries in renal ischemia. *Am J Physiol Renal Physiol*,
902 282(6), F1150-F1155. <https://doi.org/10.1152/ajprenal.00310.2001>

903 Yamamoto, Y., Ikegaki, I., Sasaki, Y., & Uchida, T. (2000). The protein kinase inhibitor fasudil protects
904 against ischemic myocardial injury induced by endothelin-1 in the rabbit. *J Cardiovasc Pharmacol*,
905 35(2), 203-211. <https://doi.org/10.1097/00005344-200002000-00005>

906 Yamasawa, H., Shimizu, S., Inoue, T., Takaoka, M., & Matsumura, Y. (2005). Endothelial nitric oxide
907 contributes to the renal protective effects of ischemic preconditioning. *J Pharmacol Exp Ther*,
908 312(1), 153-159. <https://doi.org/10.1124/jpet.104.074427>

909 Yemisci, M., Gursoy-Ozdemir, Y., Vural, A., Can, A., Topalkara, K., & Dalkara, T. (2009). Pericyte
910 contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening
911 of an occluded cerebral artery. *Nat Med*, *15*(9), 1031-1037. <https://doi.org/10.1038/nm.2022>


912 Ysebaert, D. K., De Greef, K. E., Vercauteren, S. R., Ghielli, M., Verpooten, G. A., Eyskens, E. J., &
913 De Broe, M. E. (2000). Identification and kinetics of leukocytes after severe ischaemia/reperfusion
914 renal injury. *Nephrol Dial Transplant*, *15*(10), 1562-1574. <https://doi.org/10.1093/ndt/15.10.1562>

915 Zhang, W., Bhetwal, B. P., & Gunst, S. J. (2018a). Rho kinase collaborates with p21-activated kinase
916 to regulate actin polymerization and contraction in airway smooth muscle. *J Physiol*, *596*(16), 3617-
917 3635. <https://doi.org/10.1113/jp275751>

918 Zhang, Z., Payne, K., & Pallone, T. L. (2018b). Adaptive responses of rat descending vasa recta to
919 ischemia. *Am J Physiol Renal Physiol*, *314*(3), F373-F380.
920 <https://doi.org/10.1152/ajprenal.00062.2017>

921 Zhang, Z., Rhinehart, K., Kwon, W., Weinman, E., & Pallone, T. L. (2004). ANG II signaling in vasa
922 recta pericytes by PKC and reactive oxygen species. *Am J Physiol Heart Circ Physiol*, *287*(2), H773-
923 781. <https://doi.org/10.1152/ajpheart.01135.2003>

924




926

927 **Figure 1: Ischaemia and reperfusion lead to cortical and medullary no-reflow.**

928 **(a, b)** Ischaemia and reperfusion (I/R) evoked changes of blood flow (measured by laser Doppler) in
 929 the rat renal **(a)** medulla (n=4 animals) and **(b)** cortex (n=10 animals). CONT indicates blood flow on
 930 the contralateral (non-ischaemic) side. Traces labeled +HF show the effect on recovery of perfusion of
 931 administering the Rho kinase inhibitor hydroxyfasudil (HF) immediately on reperfusion (I/R+HF) (n=4
 932 animals). **(c-e) Top:** low power views of kidney slices after perfusion *in vivo* with FITC-albumin
 933 gelatin, from **(c)** control (contralateral) kidney, **(d)** a kidney after ischaemia and 30 min reperfusion,

934 and (e) a kidney 30 mins after treatment with HF on reperfusion **Bottom:** regions of interest (ROIs) are
935 shown in red and blue for the cortex and medulla. (f) Medullary perfusion (assessed in slices of fixed
936 kidney as the total intensity of FITC-albumin summed over the ROIs) was reduced after 30 mins of
937 post-ischaemic reperfusion (51 stacks, 6 animals) by ~50% compared with control kidneys (52 stacks,
938 7 animals). Treatment with HF increased medullary perfusion 2.3-fold at this time compared with non-
939 treated ischaemic kidneys (20 stacks, 4 animals). (g) Cortex perfusion (assessed as in c-e) after 30 mins
940 of reperfusion after ischaemia was reduced by ~23.5% compared with control kidneys. Treatment with
941 HF (I/R+HF) increased cortex perfusion by 25% at this time compared with non-treated ischaemic
942 kidneys (I/R). Data are mean±s.e.m. *P* values are corrected for multiple comparisons. Statistical tests
943 used the number of animals as the N value (not the stack number).


944



945

946 **Figure 1-figure supplement 1: (a, b)** Ischaemia (I/R) evoked changes of blood flow (measured by
 947 laser Doppler) in the rat renal (a) medulla (n=3 animals) and (b) cortex (n=3 animals). CONT indicates
 948 blood flow on the contralateral (non-ischaeamic) side. At 60 min following reperfusion, medullary
 949 perfusion remained compromised at 40% of its control value ($P=0.017$), but cortical perfusion was
 950 fully recovered (to ~20% above the control value, although this did not reach significance, $P=0.092$).
 951 (c) Hydroxyfasudil (3 mg/kg; i.v.) (n=4 animals) treatment immediately after reperfusion (I/R+HF)
 952 induced a faster recovery to the pre-ischaeamic value of of medullary blood flow than did BQ123 (0.5
 953 mg/kg, i.v., given on reperfusion: I/R+BQ123) (n=3 animals), a selective endothelin-A receptor
 954 antagonist. After 30 min reperfusion both agents resulted in blood flow that was not significantly
 955 different from control ($P=0.8$ and $P=0.38$, respectively) but was significantly different from ischaemia
 956 ($P=0.01$ for both drugs). Valsartan (1 mg/kg i.v., given on reperfusion: I/R+VAL) (n=2 animals), an
 957 angiotensin II type 1 (AT1) receptor antagonist, increased medullary perfusion by 52% after 30 mins
 958 reperfusion compared with non-treated ischaemic kidneys, although this did not reach significance
 959 ($P=0.11$ vs. I/R) and valsartan had not reversed medullary blood flow to the baseline level after 30
 960 mins ($P=0.19$ vs. CONT). (d) Recovery of cortical blood flow to its control level on reperfusion was

961 faster in the presence of hydroxyfasudil (I/R+HF) (n=4 animals). BQ123 (n=4 animals) ($P=0.05$ vs.
962 I/R) and valsartan (n=3 animals) ($P=0.04$ vs. I/R) also promoted recovery of cortical blood flow at 30
963 min reperfusion compared with non-treated ischaemic kidneys (I/R). Statistical tests used the number
964 of animals as the N value.
965




966

967 **Figure 2: Ischaemia and reperfusion reduce medullary microvascular perfusion.**

968 **(a)** Representative images of slices after perfusion with FITC-albumin gelatin, showing the rat kidney
 969 microcirculation in 100 μm deep confocal z-stacks. Images depict renal cortical arterioles, the glomeruli
 970 and peritubular capillaries, as well as the vasa recta capillaries (VR) that supply blood to the renal
 971 medulla. **(b-d)** Representative images of the medullary microcirculation: **(b)** in control conditions
 972 **(CONT)**, **(c)** after ischaemia and 30 mins reperfusion **(I/R)**, and **(d)** after ischaemia and reperfusion for

973 30 mins with hydroxyfasudil (HF) applied during reperfusion (I/R+HF). Images show NG2-labelling
974 of pericytes (red), FITC-albumin labelling (green) of vessels that are perfused, a merge of the NG2 and
975 FITC-albumin images, and the analysed skeleton (yellow) of the perfused microvessels. (e-g) After
976 ischaemia and reperfusion (12 stacks, 4 animals), the total perfused capillary length (e), the number of
977 perfused capillary segments (f) and the overall volume fraction of vessels perfused (g) in 100 µm deep
978 confocal z-stacks were reduced compared with control kidneys (14 stacks, 6-7 animals), and treatment
979 with hydroxyfasudil immediately after reperfusion (10 stacks, 4 animals) increased all of these
980 parameters. Data are mean±s.e.m. *P* values are corrected for multiple comparisons. Statistical tests used
981 the number of animals as the N value (not the stack number).




982

983 **Figure 3: Ischaemia and reperfusion of renal cortex evoke no-reflow in capillaries but not**
 984 **arterioles.**

985 (a-c) Representative images of rat renal cortex slices containing arterioles, glomeruli and peritubular
 986 capillaries, after perfusion with FITC-albumin gelatin: (a) for control kidneys (CONT), (b) after
 987 ischaemia and reperfusion (I/R), and (c) after ischaemia with hydroxyfasudil (I/R+HF). NG2-labelling
 988 (red) is seen of arterioles (blue arrowheads) and pericytes (yellow arrowheads), while FITC-albumin
 989 labelling (green) shows vessels that are perfused. (d-f) After ischaemia and reperfusion (I/R) (12 stacks,
 990 6 animals), the total perfused capillary length (d), the number of perfused segments (e), and the overall
 991 perfused microvascular volume fraction (f) were reduced compared with control kidneys (CONT) (14
 992 stacks, 7 animals), and treatment with hydroxyfasudil immediately after reperfusion (I/R+HF) (10

993 stacks, 4 animals) increased cortical microvascular perfusion compared with non-treated ischaemic
994 kidneys. **(g)** Percentage of afferent and efferent arterioles (blue arrowheads in a-c), and of glomeruli
995 (white arrowheads), perfused after ischaemia, compared with control conditions. **(h-i)** Diameters of
996 perfused **(h)** afferent and **(i)** efferent arterioles in the renal cortex for the three experimental conditions
997 (15 arterioles, 4 animals for each group). Data are mean \pm s.e.m. *P* values are corrected for multiple
998 comparisons. Statistical tests used the number of animals as the N value (not the stack number).
999




1000

1001 **Figure 4: Descending vasa recta are constricted by pericytes after ischaemia.**

1002 **(a)** Descending vasa recta (DVR) in slices of rat renal medulla after perfusion with FITC-albumin

1003 gelatin (re-coloured red), and labelled for pericytes with antibody to the proteoglycan NG2 (green);


1004 FITC-albumin labeling shows perfused and blocked vessels. White arrow indicates flow direction;
1005 white lines indicate blocked vessels. **(b-c)** Representative images showing DVR capillaries blocked
1006 near pericyte somata. NG2-labelling of pericytes shows pericyte processes presumed to be constricting
1007 vessels at block site. **(d)** Percentage of DVR capillaries blocked in the renal medulla in control
1008 conditions (CONT) (127 capillaries, 12 stacks, 9 animals), after ischaemia and reperfusion (I/R) (77
1009 capillaries, 10 stacks, 6 animals), and after ischaemia with hydroxyfasudil present in the reperfusion
1010 period (IR+HF) (60 capillaries, 8 stacks, 4 animals). Statistical tests used number of animals as the N
1011 value. **(e)** Diameter at block sites. **(f)** Probability distribution per 2.5 μm bin of distance from blockage
1012 to nearest pericyte soma after ischaemia and reperfusion (for 27 block sites), and of the distance between
1013 adjacent pericytes on DVR capillaries (for 118 pericyte pairs). **(g)** DVR diameter versus distance from
1014 pericyte somata (10 μm is approximately half the separation between pericytes) in the same 3 conditions
1015 as d (number of pericytes was 31, 20 and 17 respectively). *P* values by each point are from t-tests. Slope
1016 of the best-fit ISCH regression line is significantly greater than zero ($P=0.039$) while that of the CONT
1017 line is not ($P=0.084$). Data are mean \pm s.e.m.



1018

1019 **Figure 4-figure supplement 1:** (a) Red blood cells (RBCs, indicated by yellow arrowheads, labelled
 1020 for glycophorin A) were associated with a small percentage of blockage sites (indicated by blue

1021 arrowheads) in ischaemic rat kidneys (5.8% of 85 blockages from 137 vessels analysed from 2
1022 animals), and even where red blood cells were near the capillary blockages it did not always lead to a
1023 block of blood flow (as shown by FITC-albumin, re-coloured white, passing the red blood cells [purple
1024 arrow]). Note that the vasculature was perfused with PBS to remove loose RBCs before perfusing PFA
1025 and FITC-albumin, so the only RBCs remaining should be those bound to the vessel walls. **(b)**
1026 Percentage of DVR that were blocked, and percentage of blocked DVR that had an associated RBC.
1027 **(c)** Endothelial glycocalyx (eGCX) was labelled in vivo using wheat germ agglutinin-Alexa Fluor 647
1028 (WGA, re-coloured green). White boxes show ROIs for measuring eGCX mean fluorescence
1029 intensities at different distances from the pericyte soma. **(d)** Plots of WGA signal across capillary at
1030 different distances from arrowed pericyte in (c). **(e)** eGCX is fairly evenly distributed along the vessel
1031 wall in normal kidneys (CONT), and also after ischaemia and reperfusion (I/R). Blockages (indicated
1032 by blue arrowheads) are highly associated with pericyte location (indicated by white arrowheads) in
1033 ischaemic kidneys (I/R). **(f)** Mean level of eGCX averaged across vessel at different distances from
1034 the pericyte soma in control kidney and after ischaemia with 30 mins reperfusion. For the control
1035 condition, black *P* values compare the value at each position with that at the soma. Red *P* values
1036 compare the ischaemic and control groups for each position). **(g)** eGCX mean fluorescence averaged
1037 over all positions measured. **(h)** eGCX intensity and diameter have no correlation in control or
1038 ischaemic conditions. Data are mean±s.e.m, 30 pericytes from 2 animals for each experimental
1039 condition. Statistical tests used the number of pericytes as the N value.
1040



1041


1042 **Figure 4-figure supplement 2:** Morphology of renal pericytes. (a) Cortical pericyte showing

1043 longitudinal processes and a limited number of circumferential processes. (b) Medullary pericytes

1044 showing a large number of circumferential processes.

1045

1046




1047

1048 **Figure 5: Pericytes constrict capillaries after renal ischaemia *in vivo*.**

1049 (a) Overview 2-photon *in vivo* imaging stack of the mouse renal cortex microcirculation, showing

1050 pericytes expressing NG2-DsRed (red), intraluminal FITC-albumin given intravenously (green), and

1051 Hoechst 33342 labelling nuclei (blue, 1 mg/kg in 0.5-ml of sterile, isotonic saline was administered
1052 intravenously: Dunn et al. (2016)). Images were acquired in a plane parallel to the cortical surface. **(b,**
1053 **c)** Higher magnification images showing a pericyte on a cortical peritubular capillary in control
1054 conditions, and post-ischaemic capillary block (dashed lines show path of blocked vessel). **(d)** Capillary
1055 diameter versus distance from pericyte somata after ischaemia and reperfusion (I/R), and for control
1056 kidneys (CONT) (number of pericytes was 15 and 10 respectively from 10 stacks from 3 animals from
1057 each group). Slope of the best-fit ISCH regression line is significantly greater than zero ($P=0.046$) while
1058 that of the CONT line is negative but not significantly different from zero ($P = 0.10$). Data are
1059 mean \pm s.e.m. P values comparing data at each distance are corrected for multiple comparisons.
1060 Statistical tests used number of stacks as the N value.
1061



1062


1063 **Figure 6: Pericyte contraction is mediated by α -SMA and regulated by Rho kinase.**

1064 Representative images of the rat renal medulla containing descending vasa recta (DVR) pericytes (**a-d**)

1065 and cortical peritubular capillary pericytes (**f-i**), labelled with antibody to phosphorylated myosin light

1066 chain (p-MLC, green), Alexa Fluor 647-isolectin B₄ which labels kidney tubules and pericytes (red),
1067 and DAPI which labels nuclei (blue). Labelling is shown for kidneys in control conditions (CONT) (**a**,
1068 **f**), after ischaemia and reperfusion (I/R) (**b**, **d**, **g**, **i**), and after ischaemia with hydroxyfasudil present
1069 during reperfusion (I/R+HF) (**c**, **h**). (**e**, **j**) Cortical (**e**) and medullary (**j**) p-MLC levels in pericytes for
1070 the three experimental conditions (10 stacks, 4 animals for each group). (**k-m**) DVR pericytes labelled
1071 for NG2 (purple), α -SMA (green), Alexa647-isolectin B4 (red) and DAPI (blue). (**n**) DVR blockage-
1072 associated pericyte labelled for α -SMA. Statistical tests used the numbers of animals for N values (not
1073 the stack number). Data are mean \pm s.e.m. *P* values are corrected for multiple comparisons.

1074



1075


1076 **Figure 7: Rho kinase inhibition reduces kidney injury induced by ischaemia and reperfusion.**

1077 (a-c) Images of the rat renal cortex containing proximal tubules, showing isolectin B₄ labelling kidney
 1078 tubules (red), DAPI labelling nuclei (blue), and kidney injury molecule-1 (Kim-1) labelling as an injury
 1079 marker (white lines indicate examples of injured tubules labelled in green), for control conditions
 1080 (CONT) (a), after ischaemia and reperfusion (I/R) (b), and after ischaemia with hydroxyfasudil present
 1081 during reperfusion (I/R+HF) (c). (d) Kim-1 levels for the three experimental conditions (6 stacks, 3

1082 animals for each group). Data are mean \pm s.e.m. *P* values are corrected for multiple comparisons.

1083 Statistical tests used the number of animals as the N value. (not the stack number).

1084



1085

1086 **Figure 8: Schematic diagram of loci of blood flow reductions after renal ischaemia and**
 1087 **reperfusion.** The afferent arteriole feeding the glomerulus (top arrow) and the efferent arteriole
 1088 leaving the glomerulus are little affected by ischaemia and reperfusion. In contrast, pericytes on
 1089 peritubular capillaries and the descending vasa recta (upper descending arrow) constrict the capillaries,
 1090 reducing blood flow and causing blockages as schematised at the lower right, and indicated by the
 1091 crossed lower descending arrow signifying impaired DVR flow. The resulting ischaemia leads to
 1092 kidney damage detectable by Kim-1 labelling. Hydroxyfasudil - a Rho kinase inhibitor - reduces these
 1093 effects. Created with Biorender.com.